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SUMMARY
This thesis describes the historical development of our knowledge of 
prostaglandins and thromboxane and the synthesis, metabolism and 
actions of prostacyclin and thromboxane. Chapter 3 then presents work 
on the development and validation of a radioimmunoassay to measure 
plasma prostacyclin metabolite levels. Comparisons are made of 
results using a tritiated and an iodinated radioactive label and also 
of results obtained using different antibodies. Results are also 
presented of an assay to measure prostacyclin stimulating factor in 
normal plasma and serum. A method developed to measure endothelial 
cell prostacyclin production using a human umbilical artery perfusion 
model is described.
Chapter 4 describes the various methods which may be used to measure 
production of thromboxane A^. Firstly a radioimmunoassay is 
described which measures thromboxane B2  the stable metabolite of 
thromboxane & 2  results using this assay for both plasma and
serum samples are produced. Methods for measuring thromboxane 
generation by platelets in response to aggregation with 4 ug/ml of 
collagen and also serum thromboxane B2  levels in bleeding time blood 
are described.
The second part of the thesis is concerned with an attempt to validate 
the relevance of the prostacyclin/thromboxane balance in clinical 
situations.
Possible ways of altering the thromboxane/prostacyclin balance which 
» Y  have clinical implications were explored.
Plasm levels of prostacyclin metabolites and thromboxane before 
and after ingestion of drugs known to alter arachidonic acid 
metabolism are shown. Studies on the effect of dietary fat intake and
smokii^ on the prostacyclin/thromboxane balance are presented.
XV
Chapters 6 and 7 examine the thromboxane/prostacyclin balance in a 
range of vascular diseases and in bleeding disorders respectively. A 
Chapter is then devoted to the possible relevance of the 
thromboxane/prostacyclin balance in pregnancy and associated disorders 
of pregnancy. Chapter 9 summarises the results of this work and also 
discusses the implications for future research.
All the statistics in this thesis unless otherwise stated, use 
Wilcoxon's rank sum tests on paired or unpaired data as described in: 
Statistics at Square One Ed T D V Swinscow, British Medical 
Association, London
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CHAPTER 1 - HISTORICAL INTRODUCTION AND OVERVIEW
1.1 Discovery of Prostaglandins
In 1930 in New York a gynaecologist Dr Raphael Kurzrok, vhose 
particular interest was artificial insemination, discovered that 
lipid fractions isolated from human semen increased the 
contractile response of the uterine muscle. Kurzrok and his 
colleague Lieb carried out a series of in vitro experiments using 
human uterine strips obtained after hysterectomy. They
discovered that the same sample of semen was able to produce 
contraction in one uterine strip but not another. Moreover they 
found that one uterus contracted in response to one semen sample 
but dilated on exposure to another. They were also able to find 
correlations between the contractile response and the patient's 
history of infertility. Other workers soon became interested in 
these experiments. In 1935 Goldblatt attributed the biological 
activity of seminal plasma to a lipid or lipid like substance 
(Goldblatt 1935). Von Euler (1936) was the first to call this 
active substance prostaglandin supposing, wrongly as it later
turned out, that it was produced by the prostrate gland. Von
Euler (1936) also reported similar activity in extracts prepared
from seminal vesicles of sheep. He proposed that the active 
component had the properties of a fatty acid. Sheep seminal 
vesicles still remain the best biological source of prostaglandin 
intermediates and end products.
At this stage of development the work was unable to progress much 
further mainly due to the lack of sc^histicated analytical 
techniques and equipment.
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It had to wait another thirty years until Bergstrom and 
colleagues (Bergstrom 1964) in association with van Dorp in 
Holland (Van Dorp 1964) were able to isolate the first pure 
prostaglandin and elucidate its structure. Initially Bergstrom 
designated a fraction as "active" if it induced smooth muscle 
contraction in rabbit duodenum and caused the rabbit's blood 
pressure to drop. However the introduction in the 1960's of 
gas-liquid chromatography and mass spectometry (GCMS) (Ryhage 
1960) allowed further characterisation of these "active" 
prostaglandin fractions. It soon became apparent that 
prostaglandins were ubiquitous, their precursors being identified 
by Bergstrom (1964) and by Van Dorp (1964) as unsaturated fatty 
acids such as arachidonic acid.
Synthesis of prostanoids can apparently take place in all tissues 
from arachidonic acid incorporated in the phospholipids of cell 
membranes. The products are formed and released as a result of 
various stimuli: mechanical, chemical, immunological and
others. It was found that many of the prostanoids were unstable 
and measurement of stable metabolites using sensitive assay 
methods could often give a clearer picture. Several of these end 
products were themselves found to possess biological activity. 
After having reached the circulatory system most prostaglandins 
are rapidly metabolised, the main inactivation occurring in the 
lungs and the liver by the action of a dehydrogenase. 
Prostaglandin A^ however is not attacked by this dehydrogenase 
and thus exerts a prolonged action.
One of the most significant discoveries in the prostaglandin 
story was the demonstration by Vane and colleagues that 
prostaglandin synthesis could be inhibited by aspirin (Vane 1971).
— 2 —
This provided a new tool in the study of these conpounds. 
Valuable information can be provided on the action of a 
biological substance by its inhibition and this greatly extended 
knowledge of the biological role of prostaglandins.
Figure 1 shows the pathways of arachidonic acid metabolism in 
human platelets and endothelial cells.
1.2 Nomenclature of Prostaglandins
There are nine classes of naturally occurring prostaglandins 
which have been discovered up to this time. Figure 2 shows the 
structure of each of these nine classes.
The first successful purification of a prostaglandin was achieved 
by partition of the crude mixture between ether and phosphate 
buffer. Prostaglandin E was obtained from the ether phase and 
/ prostaglandin F from the aqueous phase (fosfat). Treatment of 
prostaglandin E with acid gave prostaglandin A and treatment with 
a base gave prostaglandin B. When other prostaglandins were 
discovered they were given appropriate letters to complete and 
extend the sequence. The subscripts 1, 2 etc are used to signify 
the number of double bonds in the side chains of the 
prostaglandin. The numbering of prostaglandins is conventional, 
the number one being given to the carbon atom of the principal 
group. In the F series of prostaglandins the subscript refers 
to the configuration of the hydroxyl group attached to C-9.
The thromboxanes have an oxacyclohexane ring in place of the 
cyclopentane ring of the prostaglandins.
-  3 -
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Two classes of thromboxane have been isolated and their structure 
is shown in Figure 3.
Thromboxane A
OH
I
O
Thromboxane B
Figure 1.3 - Structure of thromboxanes
1.3 Discovery of thromboxanes
Piper and Vanê• (1-969)'first demonstrated the rèleasè from guinea 
pig isolated perfused lungs of a previously unknown substance 
which potently contracted rabbit aortic strips and many other 
isolated vascular smooth muscle preparations. They first called 
it rabbit aorta contracting substance or RCS. This RCS was found 
to have a half life of less than two minutes at 37^C and its 
release was caused by a variety of stimuli including antigen 
challenge of sensitised lungs. The release could be blocked by 
aspirin-like drugs which suggested that RCS was from the same 
family as the prostaglandins. As the unstable prostaglandin 
endoperoxides also contract rabbit aorta it was first suggested 
that RCS was an endoperoxide. However its half life was shorter 
than that of the endoperoxides (about 5 minutes).
— 4 —
Furthermore the amounts of endoperoxide present in lung effluent 
were insufficient to account for the rabbit aorta contracting 
ability. It was found that RCS was released by aggregating 
platelets (Hamberg 1975) and this led to the discovery of its 
structure. Hamberg and colleagues (1975) isolated the highly 
unstable intermediate in the conversion of prostaglandin H2  to 
thromboxane B2  (TXB2 ) and called it thromboxane A 2
(TXA2 ). It has a half life of only about 30 seconds at 37°C 
and is more active than PGH2  in contracting rabbit aorta. It 
is the major constituent of the previously discovered RCS. 
Thromboxanes were so called because of their ability to produce 
thrombosis via aggregation of blood platelets. Ihe structure of 
TXB2  has been fully elucidated but the structure of TXA2  is 
based only on chemical and mass spectral data.
1.4 Discovery of prostacyclin
Prostacyclin (PGI2 ) was first described by Moncada and Vane
(1976). Ihe discovery arose from experiments designed to 
investigate the theory that damaged blood vessels might produce 
TXA^ which could act synergistically with that produced by
platelets. It was found however that when blood vessels were 
incubated with endoperoxides it was not TXA2  that was produced 
but a substance with opposite properties. It caused inhibition 
of platelet aggregation and induced relaxation of vascular smooth 
muscle. This substance was initially called PCX before its 
structure was elucidated in collaboration with scientists from 
the Upjohn Company (Johnson 1976) when it was renamed
prostacyclin.
-  5 -
PGI2  is generated by blood vessel microsomes or fresh vascular 
tissue from the prostaglandin endoperoxide PGH2  (Bunting 1976, 
Moncada 1976). Later it was shown that fresh vascular tissue 
could also utilise arachidonic acid as a substrate for PG% 2  
production though the endoperoxides are much better substrates 
(Bunting 1976). It has been suggested that the vessel wall is 
able to synthesise PGI^ from its own endogenous precursors or 
from prostaglandin endoperoxides released by the platelets. This 
would indicate biochemical co-operation between the platelets and 
the vessel wall (Gryglewski 1976). Tansik (1978) showed that 
lysed aortic smooth muscle cells could be supplied with 
prostaglandin endoperoxides by lysed human platelets. Marcus 
(1978) also showed that undisturbed monolayers of endothelial 
cells readily transform PGH2  to PGI2 . Needleman (1978) 
however showed that perfused rabbit hearts rapidly converted 
arachidonic acid to PGI2  but that PGH2  was not readily 
transformed and they concluded that vascular damage was necessary 
for the endoperoxide to be utilised by PGI2  synthetase.
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CHAPTER 2 - SYNTHESIS, ACTION AND METABOLISM OF 
THROMBOXANE AND PROSTACYCLIN
2.1 Introduction
Prostaglandins are a family of oxygenated fatty acids synthesised 
by nearly every tissue in the body which have been detected in 
the venous effluent from numerous mammalian organs. 
Prostaglandin release can be stimulated by hormones, nerve 
stimulation, mechanical damage and decreased oxygen tension. 
Prostaglandins are thought to act as local hormones which are 
synthesised near to their site of action and then rapidly 
inactivated (autacoids).
Arachidonic acid, the precursor of all bis-enoic prostaglandins 
can be obtained direct from the diet or by anabolic desaturation 
and chain elongation from the dietary essential fatty acid, 
linoleic acid. In cell membranes arachidonic acid is 
incorporated as a structural component of phospholipids in all 
body tissues. The general structure of a phospholipid is shown 
in figure 2.1.
base ]PHOSPHATE
unsaturated FATTY 
ACID
saturated FATTY 
ACID
Figure 2.1 - General Structure of a Phospholipid
—  1 —
The three major membrane lipids are phospholipids, glycolipids 
and cholesterol. Phospholipids are derived either from glycerol 
or sphignosine, a more complex alcohol. Phospholipids which are 
derived from glycerol are more specifically called 
phosphoglycerides. There are a variety of phospholipases which 
act at different sites on the phospholipid. Phospholipase 
(PLA^) catalyses the hydrolysis of the ester bond of the 2-acyl 
group, the source of the unsaturated fatty acid arachidonic 
acid. Cyclic AMP inhibits PLA^ formation and it is stimulated 
by thrombin and collagen. Phospholipases can be activated by 
changes in the chemical environment or by mechanical 
stimulation. Figure 2 shows diagramatically arachidonate release 
and subsequent formation of oxygenated products.
Cell membrane phospholipids
s pec i f i c  
s t e r o i d - i nduced  — 
i n h i b i t o r y  prot ei n
phosphol i pase 
<------------ c y c l i c  AMP regul at i on -t-or —
f ree"^-arachidonate
I i poxygenase cycl ooxyqenase
l eukot r i enes ^ ^  pr os t agl andi ns
th romboxanes
NSAID
inhib i t ion
Figure 2.2 - Arachidonate release from membrane phospholipids and 
subsequent formation of oxygenated products
2.2 Essential Fatty Acids
Polyunsaturated fatty acids from which prostaglandins are derived 
were known to be essential to the diet before the discovery of 
prostaglandins and were thus termed essential fatty acids 
(EFA's). In the late nineteen twenties Burr and Burr (1929) 
found that rats which were fed on a diet devoid of the fatty acid 
fraction of fats developed a deficiency syndrome. This led them 
to conclude that the active principle was linoleic acid. Similar 
results were obtained with y -linoleic acid and arachidonic 
acid. It has since been shown that the metabolism of arachidonic 
acid leads to prostaglandins of the 2-series in mammalian 
systems. The corresponding 1-series prostaglandins are derived 
from dihomo-y-linoleic acid and the 3-series from 5, 8, 11, 14, 
17 - eicosapentaenoic acid. So far as is known the 2 and 3 
series prostaglandins are biosynthesised by analogous pathways to 
the arachidonic acid pathway. Arachidonic acid is stored in 
cells in various esters. The phospholipids of cell membranes 
contain large amounts of arachidonic acid as the phosphatidyl 
esters of choline, inositol, serine and ethanolamine. Release of 
arachidonic acid is calcium dependent and achieved by the action 
of specific phospholipases. Type I phospholipases are bound to 
cellular membranes and their enzymatic activity is related to the 
membrane stability. Type II enzymes are soluble and found in 
many mammalian cells. Interestingly these type II enzymes are 
similar to phospholipase A^ enzymes found in the venoms of 
certain poisonous snakes and in bees and wasps. It may be that 
this leads to the release of vasodilatory prostaglandin which 
speeds up the release of the poison into the circulation.
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PLA2  has also been found in the lung, intestine, thyroid, 
soninal fluid and placenta. Certain activating and inhibitory 
factors are known to influence the activity of PLA2  enzymes.
2.3 Cyclo-oxygenase Pathway
When arachidonic acid is released it activates both the 
cyclo-oxygenase and lipoxygenase enzymes. Cyclo-oxygenase, which 
is the prostaglandin synthetase, is really a group of enzymes 
which convert arachidonic acid or other 20-carbon unsaturated 
fatty acids into an endoperoxide configuration. These 
endoperoxides are the key precursor molecules for all subsequent 
prostaglandin and thromboxane production (see Figure 1.1).
The first step in endoperoxide formation involves the interaction 
of one molecule of arachidonic acid with two molecules of oxygen 
in the prostaglandin cyclo-oxygenase enzyme system to form the 
bicyclic endoperoxide PGG^. Peroxidase activity results in the 
cleavage of the C-15 hydroperoxide to from the hydroxyl group 
present in PGHg. The cyclo-oxygenase activity is still not 
fully understood but appears to catalyse the destruction of the 
enzyme itself. Nearly all tissues synthesise PGG2  and PGHg. 
There is still controversy as to whether the further conversion 
of PGH^ to the so-called "primary prostaglandins": PGD^,
PGE2  and PGF2  is catalysed by an enzyme. It is believed that 
PGF2  is a non-enzymatic product of the endoperoxides and might 
therefore be expected to be a constant component of any mixture 
of cyclo-oxygenase products especially where the enzyme pathways 
are blocked.
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The actual mixture of products formed shows marked cell and 
tissue specificity. Different cell types in culture have 
different patterns of cyclo-oxygenase products. In some tissues 
such as kidney, uterus and lung different areas form different 
mixtures of cyclo-oxygenase products (Downing 1980, Schulman 
1982, Sraer 1982). As well as cell and tissue specificity it has 
been shown that there are species differences. In rabbits and in 
humans the major cyclo-oxygenase product in the lungs is 
prostacyclin (Alabaster 1980), whereas in the guinea pig lung it 
is thromboxane A^ (Uotila, 1980). This species specificity 
means that it is inappropriate to compare results obtained from 
animal models to the human situation.
2.4 Synthesis of Thromboxane
In most biological systems more than one prostaglandin together 
with thromboxane A2  (TXA2 ) is the normal mixture of 
cyclo-oxygenase products. Generally at higher substrate 
concentrations TXA2  synthesis will increase disproportionately 
{ to prostacuclin (PGI2 ) synthesis. The synthesis of TXA2  from 
the endoperoxides is catalysed by a thromboxane synthetase enzyme 
which is found primarily in the microsomal fraction of virtually 
every cell type except the erythrocyte in mammalian species. 
TXA2  differs in structure from the prostaglandins in that the 
cyclopentane ring is replaced by a six-membered oxane ring (see 
Figure 1.3). A variety of aggregating agents such as thrombin, 
collagen and epinephrine stimulate TXA2  formation by 
platelets. The aggregating effects of low, but not of high 
concentrations of these aggregating agents can be blocked by 
cyclo-oxygenase inhibitors.
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Work by Serneri and colleagues (1983) indicates that human 
arterial and venous vessel walls are able to synthesise TXA2 . 
They showed progressive generation of TXB2 , when measured by 
radioimmunoassay for up to forty minutes incubation time. They 
also showed that TXA2  production was lower in arteries fran 
women than those from men, which is the opposite from what has 
been found with PGI2  production (Masotti 1981). It appears 
that TXA2  is produced by the media and PGI2  by the 
endothelial cells. More recent work by Orlandi (1985) using 
platelet free monocytes from human peripheral blood has shown 
that activated monocytes are capable of producing at least as 
much thromboxane as activated platelets, but it is not yet clear 
whether it is TXA^ or TXB2  which is produced. TXB2  has 
also been shown to be synthesised by parenchymal cells prepared 
from diseased livers removed after partial hepatecton^ but not by 
cells from normal livers (Spolarics 1984). This supports the 
theory that prostaglandins and thromboxanes may be involved in 
liver regeneration.
2.5 Action of Thromboxane
The short half life of TXA2  and difficulty of preparation means 
that studies on its actions on whole animals are very limited. 
TXA2  aggregates platelets, being more potent than PGG2 , and 
PGHg and it would seem likely that under normal circumstances 
in vivo these endoperoxides cause platelet aggregation through 
conversion to the more potent TXA2  (Moncada 1979).
TXA2  powerfully contracts guinea pig and human airway smooth 
muscle in vitro and bronchoconstriction following intravenous 
administration to the anaesthetised guinea pig has been shown 
(Svensson 1977). Guinea pig lung readily produces TXA^ and it
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is possible that TXA^ mediates part of the bronchoconstriction 
of anaphylaxis in this species. It appears that human lung does 
not produce TXA2  though human airways respond to it. It is 
therefore difficult to see how TXA2  could contribute to 
asthmatic broncho-constriction although increased levels of 
TXB2  have been reported during asthmatic attacks. TXA2  has a 
weak contractile action relative to PGE2  and PGF2  and on 
gastrointestinal smooth muscle. It has also been reported to 
contract human and guinea pig, but not rat, uterine smooth muscle 
in vitro.
TXB2  has been reported to have weak contractile activity on 
some isolated smooth muscle preparations but as it is very many 
times less potent than TXA2  this is unlikely to be of any 
physiological significance.
2.6 Metabolism of Thromboxane
TXA2  is very labile, having a half life of approximately thirty 
seconds in aqueous media at 37°C. The hydrolyses of TXA2  
occurs spontaneously but may be enzyme assisted in vivo. In man 
^-oxidation is the major metabolic pathway by which TXB^ is 
degraded and 2,3 - d inor - TXB2  is the major urinary
metabolite (Roberts 1977).
2.7 Sites of Prostacyclin Synthesis
After the initial studies of PGIg synthesis with arterial and 
venous strips (Raz 1977, Johnson 1976) or with arterial 
microsomes prepared from homogenates of whole arterial walls 
(Bunting 1976), Moncada and colleagues examined differential 
formation by layers of rabbit aorta (Moncada 1977).
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They found that although the intima comprised only 5% by weight 
of the rabbit aorta it produced 40% of the PGI2 , with the media 
coming next and adventitia last. Porcine (McIntyre 1978) and 
bovine (Weksler 1977) aortic endothelium and human umbillical 
vein endothelium (Weksler 1977) have all been shown to produce 
PGlg. In most species tested arteries produced more than veins 
by weight of tissue (Kent 1981). Foetal tissue has been shown to 
be more active than adult tissue in the conversion of arachidonic 
acid to PGI2  (Terragno 1978). The placenta is also capable of 
producing large amounts of PGI^ (Myatt 1977). It has also been 
shown that cultured endothelial cells can produce more PGI2  
than smooth muscle cells (Boenziger 1977 and 1980).
2.8 Actions of Prostacyclin
2.8 (a) Action on Platelets
PGI2  is the most potent known naturally occurring inhibitor of 
platelet aggregation being up to forty times more potent than 
PGE^ and PGD^ in vitro. Not only does PGI2  inhibit 
platelet aggregation, but it can also disaggregate already 
aggregated platelets (Ubatuba, 1979). PGI2  inhibits platelet 
activation at several metabolic steps : it elevates cyclic AMP
thus activating a cyclic AMP dependent protein kinase that 
phosphorylates myosin kinase which in turn decreases the 
phosphorylation of myosin, reduces actin-myosin interaction and 
inhibits the release reaction. Aggregation of platelets by all 
known aggregating agents is inhibited by PGI2  and secretion of 
platelet vasoactive mediators is also inhibited (Bunting 1981).
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Ristocetin-mediated agglutination of washed, fixed platelets is 
not inhibited by PGI2  whereas the ristocetin induced
aggregation mediated by the release reaction is inhibited (Moake 
1981), Inhibition of aggregation is dose dependent on the 
concentration of PGI2 . Patients receiving infusions of PGI2  
have prolonged bleeding times (Ubatuba, 1979), but although 
PGI2  has a profound effect on platelet aggregation it has not 
been found to have any direct action on blood coagulation 
(Blasko, 1979). PGIg also prevents shape change in platelets
(Ehrman 1980) but has less effect on platelet adherence to the 
subendothelium. Adhesion is only inpaired at concentrations 
>10GnM (Weiss 1979, Czervizoke 1978, Curwen 1980, Adelman 1981). 
However aggregation of platelets on a single adherent layer is 
readily inhibited by PGI^.
2.8 (b) Vasodilation
With the exception of pig coronary artery, PGI2  causes 
vasodilation and relaxes smooth muscle in all mammalian species 
tested. The degree of vasodilation and relaxation varies from 
species to species and with the vascular bed. When PGI2  is 
administered to humans, flushing is often apparent within one
minute of the start of the infusion and, in some subjects, may 
remain for some time after the infusion is stopped. PGI2  has 
potent actions on the kidney, causing vasodilation, increased 
urine formation and electrolyte excretion (Baer 1979, Hill
1979). PGI2  dilates the blood vessels of the stomach and is 
the major cyclo-oxygenase product of the gastric mucosa of 
several species (Gerkens 1978, Whittle 1980, Salvati 1981).
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2.8 (c) Receptors
f In 1905 Langley observed that cells contain a ‘receptive
!
' substance' as well as the 'chief substance' concerned with
secretion or contraction and that the receptive substance affects 
the metabolism of the chief substance and that not only 
neur(muscular drugs but also internal secretions probably act 
upon receptive substances (Langley 1905). A few years later 
Ehrlich proposed that highly specific side chains are present in 
the cell protoplasm and these chemically unique structures could 
serve as receptors with v4iich chemotheraputic drugs ccanbine 
(Ehrlich 1913). Since that time there has been great expansion 
of knowledge of receptor structure and function but these basic 
concepts have remained essentially unchanged. In 1956 it was 
discovered that 'spare' receptors are available for drugs and 
hormones (Stephenson 1956). It has been shown that [^ H] PGIg 
binds to a particulate fraction of platelets from various species 
including man (Siegl 1979, Miller 1979, Schillinger 1980).
PGIg receptors have also been demonstrated on red blood cells 
(Willems 1981). On platelets PGI^ and PGE^ occupy the same 
receptor site. 6-keto-prostaglandin Fl^ C, the stable hydrolysis 
product of PGIg, does not bind to the PGI^ receptor site and 
therefore does not interfere with the binding of PGIg to 
platelets (Miller 1979). PGI2  prevents the expression of
I fibrinogen receptors on the platelet surface (Hawiger 1980).
/
2.9 Metabolism of PGIq
In biological fluids PGI2  has a half life of only three minutes 
(Dusting 1978), being hydrolysed to the stable 
6-keto-prostaglandin FloC (6-keto-PGFloO. This is the metabolite
—  16 —
which is most commonly measured as as index of PGI^
production. In vitro PGI2  is a substrate for the 
15-hydroxyl-PG-dehydrogenase enzyme of lung tissue and blood 
vessels (McGuire 1978, Sun 1978) but 6 -keto-PGFl0 6  is a much 
poorer substrate (McGuire 1978), perhaps due to the hemiketal
structure limiting accessibility for the enzyme. At the tissue 
level any PGI2  generated may therefore be metabolised through a 
bicyclic 15-keto derivative and thus estimations of tissue PGI2  
output may be misleading if based on 6-keto-PGFlod measurements 
alone. Unlike the primary prostaglandins where greater than 90%
is inactivated in one passage through the lungs (Ferreira 1967),
PGIg suffers no loss in biological activity (Bolger 1978, 
Dusting 1978). Furthermore the lung has been found by some 
workers to produce PGI2  and release it into the arterial 
circulation (Gryglewski 1978, Hensby 1979). This together with 
the lack of pulmonary inactivation has been used as evidence to 
support the theory that PGI^ is a circulating homone (Moncada 
1978). Other investigators however have failed to obtain 
evidence of pulmonary production (Smith 1978, Pace-Asciak 1980), 
More recent work measuring urinary metabolites also suggests that 
PG% 2  is not a physiologically important circulating hormone in 
normal man (Fitzgerald 1981). However even if this is true it 
does not preclude an important role for PGI2  in the local 
regulation of platelet-vessel wall interaction. In other organs 
such as the liver and kidneys metabolism of PGI^ seems to be 
similar to that of the primary prostaglandins (Dusting 1978, 
Ferreira 1978).
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Although PGI^ is not metabolised enzymatically in the lungs, as 
shown in experiments with rats (Sun 1978), there may be 
substantial enzymatic metabolism in the blood vessels. 
Measurement of urinary metabolites in rats has shown that any 
PGIg enzymatically metabolised is rapidly hydrolysed to 
6-keto-PGFlod even when infused over an extended period (Sun 
1978). There has been less work done on human PGI2 metabolism 
than in animals. However what has been done suggests that PGI2  
infused into the systemic circulation is not degraded by the 
15-hydroxyl-PG-dehydrogenase initially, due to poor specificity 
for tissue uptake systems (Hawkins 1978). The suggestion from 
the rat experiments (Sun 1978) of substantial enzymatic 
metabolism in the blood vessels does not appear to be true in 
man. Using a radioimmunoassay to measure 13, 14-dihydro-6, 
15-dioxo-PGFl odit would appear that little of this conpound is 
produced during infusions of either PG% 2  or 6-keto-PGFloC (Myatt 
1981). However during prolonged low dose infusions or from 
endogenous production, PGI2  may be locally metabolised 
enzymatically before appearing in the circulation. In vivo this 
may be a major source of 13, 14-dihydro-6, 15-dioxo-PGFlo<, and 
therefore measurements of 6-keto-PGF^oc in the systemic 
circulation will not take this into account. The enzyme 
9-hydroxyl PG dehydrogenase which converts PGF conpounds into the 
corresponding PGE compounds has been identified in both rabbit 
and rat kidney (Hoult 1978, Pace-Asciak 1975). The contribution, 
if any, of this enzyme to the metabolism of PGI2  in man is not 
yet known.
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CHAPTER 3 - MEASUREMENT OF PROSTACLYCLIN AND ITS METABOLITES
3.1 Introduction
Since the discovery of PGI^ workers have been trying to 
determine its role in various pathological conditions in man. In 
order to try to elucidate its contribution, ways must be found to 
determine whether or not PGI^ is present in the body tissues or 
fluids in question and to try to measure its production. The 
general characteristics of the various methods which can be used 
will be discussed in this chapter and detailed descriptions of 
the methodology developed for this thesis will be given.
3.2 Bioassay
Any reproducible, dose dependent biological response can be used 
as the basis for a bioassay. As with any other assay, the 
relative usefulness of a bioassay depends on its sensitivity,
, specificity, reliability and simplicity. Although theoretically
: possible, in vivo bioassay techniques are now seldom used for 
ethical reasons. Originally bioassay was the method used for the 
detection of PGI^ due to its potent inhibitory action on 
platelet aggregation and its ability to disaggregate already 
aggregated platelets. The method has contributed much to our 
knowledge of prostaglandins in general and made possible the
original discovery of PGI2 . Bioassay has the ability to detect 
unexpected biologically active substances in an experimental 
situation which is rarely true of chemical methods. There has 
been much interest in the use of isolated preparations of 
arteries and veins because of their ability to differentiate
between the various prostaglandins and thromboxanes. If the
assay organ is carefully chosen a characteristic response to the
test substance can be shown.
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Although sensitive, bioassay methods can however never be 
absolutely specific and are difficult to use quantitatively. The 
method also has a low sample capacity. Bioassay is of use mainly 
when looking for the presence of biologically active compounds or 
when dealing with substances of an unknown nature.
3.3 Gas chromatography and mass spectometry
Techniques for the measurement of prostaglandins based on gas 
chromatography and mass spectometry (GCMS) were developed in 
order to provide methods with greater specificity. The basis of 
the method is the addition of a deuterated compound to a sample. 
After purification and derivatisation the ratio between 
deuterated and non-deuterated molecules is measured with the mass 
spectrometer. From knowing the amount of added deuterated 
compound the amount of unlabelled compound can easily be 
calculated. Since the deuterated molecules have physical 
properties almost identical to the unlabelled molecules they 
co-chromatograph during most purification systems and therefore 
the labelled molecules serve as carriers during purification and 
derivatisation and as internal standards during the final gas 
chromatographic mass spectometric analysis. The preparation of 
good carrier molecules is of vital importance.
A highly specific method for the measurement of 6-keto-PGFloC 
using negative-ion chemical ionization mass spectrometry has been 
developed (Barrow 1982) and has been used to measure 6-keta-PGFloi 
concentrations in human plasma (Blair 1982). Using this method 
they found normal concentrations to be in the range 0.5 - 2.5 
pg/ml suggesting that PGI^ is not a circulating hormone in man 
under normal conditions, but a locally acting substance released
in response to local stimuli (Ritter 1983).
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However it has been shown that only a proportion of PGI^ 
metabolites are 6-keto-PGFloC(Rozencranz 1981) and therefore GCMS 
may not be the best method when examining variations in PGI^ 
production rather than absolute levels of 6-keto-PGFlc^. Although 
the use of sophisticated techniques such as GCMS often raise the 
confidence in a particular result, care must be taken in the
interpretation of results. The method is also susceptible to 
methodological problems. For example the electron inpact 
ionisation is dependent on the gas phase collision between the
molecule being analysed and a high energy electron. During the
ionisation process, excess internal energy is imparted to the
molecule. The energy is dissipated by the fragmentation 
reactions which occur in the source of the mass spectrometer. 
This can cause loss of sensitivity or specificity in the anlysis 
of prostaglandins (Blair 1983). Also the gas chromatography 
method of analysis generally uses prostaglandin analogues as 
internal standards and this can also lead to problems with 
specificity. However in many laboratories perhaps the biggest 
problem with this method of analysis is the availability of 
equipment. Highly sophisticated and expensive equipment is 
required which is not always available. The method also has a 
low sample capacity and requires a fairly large initial sample 
volume in comparison to other methods.
3.4 Radioimmunoassay - Introduction
Radioimmunoassay (R.I.A) has advantages over other quantitative 
methods : it is possible to obtain high sensitivity with very low 
limits of detection; specificity may be considerable;
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large numbers of samples can be assayed within a reasonably short 
period of time; the precision and accuracy compare favourably 
with other methods and, apart from a radioactivity counter, no 
sophisticated laboratory equipment is necessary. As our interest 
was in trying to determine the role of PGI2 and thromboxane in 
various pathologic conditions and this involved measurement of 
levels of these substances in large numbers of sairples, we put 
considerable effort into the development of a specific, sensitive 
! and reproducible RIA for the measurement of PGI2  metabolites.
3.5 History of Radioimmunoassay
Radioimmunoassay may be said to have developed as a by-product in 
the development of nuclear weapons. With many radioactive
isotopes the energy of their emission is so great that it is
possible to detect a few atoms with relatively simple equipment. 
If such atoms are attached to another molecule then it can also
be detected in equally small amounts. In the mid 1950's Yalow
and Berson were studying ^^^I-labelled insulin and showed that 
insulin requiring diabetics almost always have a circulating 
insulin-binding protein (Berson et al 1956). At the same time as 
demonstrating the binding of ^^^I insulin by this binding 
protein they also showed that the labelled tracer could be 
displaced from the binding sites on the antibody by the addition 
of large amounts of unlabelled insulin. They then showed that 
the degree of binding of the tracer was quantitatively related to 
the amount of unlabelled insulin present. This observation led 
■ to the first radioimmunoassay for insulin (Yalow & Berson 1971) 
after the development of a specific antisera to human insulin by 
the immunisation of guinea-pigs (Yalow & Berson 1960).
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Originally iodination involved handling large amounts of 
radioactive isotopes and could therefore only be carried out by 
highly specialised laboratories. The development of the 
chloramine T iodination procedure by Greenwood et al (1963) was 
one of the most important in the advancement of RIA to the stage 
where it is at today with numerous commercial kits available for 
the measurement of many different conpounds.
3.6 Principle of Radioimmunoassay
RIA is based on the coirpetition between labelled and unlabelled 
molecules of a particular compound for binding sites on an 
antibody directed against that compound as shown in figure 3.1.
The amount of labelled compound is known and constant in all the 
tubes but the amount of unlabelled compound is known and varied 
to obtain a standard curve. The sample tubes contain constant 
volumes with unknown amounts of the compound in question, sample 
values can later be extrapolated from the standard curve. Each 
assay must also have tubes with no antibody present to give 
non-specific binding (NSB) and also tubes with no unlabelled 
compound to give maximum binding. In the presence of few 
unlabelled molecules a large proportion of the labelled ones are 
bound to the antibody. As the amount of unlabelled molecules 
increase the amount of labelled molecules bound decreases 
quantitatively. The situation can be described by the law of 
mass action which states that : at equilibrium, the ratio of the 
products of the concentrations on the two sides of the equation 
will be a constant K.
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[Ag Ab] = K 
[Ag] [Ab]
Where [Ag], [Ab] and [Ag Ab] are the concentrations of the free 
antigen, free antibody and antigen-antibody complex
respectively. The k value for any system provides a measure of
the energy of the reaction between the antigen and antibody.
Given an unvarying quantity of antibody of fixed k value, the 
ratio of bound to free ligand at equilibrium will be
quantitatively related to the total amount of ligand present. 
This is the basic principle of all radioimmunoassays.
3.7 Development of a Radioimmunoassay for Prostacyclin Metabolites
3.7 (a) Problems
Because of the short half life of PGI^ most workers have 
attempted to measure 6-keto-PGFloC the stable hydrolysis product 
when looking for an index of PGI^ production. In the 
literature there are vast differences in the published 'normal' 
plasma levels. Even when examining results obtained with GCMS 
assays, which is considered to be highly specific, results range 
from 200 ng/1 (Hensby 1979) to as little as 3ng/l (Blair 1982). 
When results of assays using RIA are compared there are still 
large differences in 'normal' plasma levels as is shown in 
Table 3.1.
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6-keto-PGFl
levels (pg/ml) Authors
115 + 24 Mitchell 1978
123 + 22 Lewis 1980
690 + 386 Kinney 1981
69.6 + 11.6 Gullner 1982
93 +42.3 Ylikorkala 1982
4.7 + 3.2 Seiss 1982
7.5 Patrono 1982
64 + 14 Roy 1983
13.7 + 1.8 Gotoh 1983
270 + 14 Uehara 1983
36 + 4 Brandt 1984
27 + 3 Swartz 1985
Table 3.1 : Range of published 'normal' levels of plasma 
6-keto-PGFloC
3.7 (a) (i) Extraction Procedures
In radioimmunoassay, samples may often require to be extracted 
before the performance of the assay. There are two reasons for 
extraction : firstly to inprove the sensitivity, the endogenous 
ligand may be concentrated, and secondly, if the assay is not 
sufficiently specific, the endogenous ligand must be separated 
from other materials. Extraction procedures can be divided into 
two common types : those in which the ligand in the sample is 
absorbed to particulate material and is thus easily separated 
from unadsorbed components; and those in which the sample is 
treated with an immiscible organic solvent which extracts the 
1igand.
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Absorption methods are normally used where the ligand must be 
separated from other components in the sample. The majority of 
methods described for the assay of plasma 6-keto-PGFlpd involve an 
extraction step prior to RIA. However it has been shown by 
Greaves et al (1982) that organic extraction and to a lesser 
extent, silicic acid chromotagraphy may themselves introduce 
artefact. Measurable levels of 6-keto-PGFl were found in a 
sample of distilled water which was subjected to the same 
extraction procedures as used on plasma samples.
They found that this blank value could be reduced by dilution of
the sanple but the curve obtained did not match the standard 
curve for the assay. Thus any attempt to "correct" for the blank 
by simply subtracting it from the sample is completely invalid. 
Unless extensive purification is carried out after extraction 
these procedure blanks are almost invariably seen (Granstrom 
1978). Greaves (1982) found that three separate purification 
steps were necessary after extraction before the blank value was 
removed. Therefore if absolute values of 6-keto-PFGloC are to be 
measured it is vital that this extensive purification is 
performed on every sample prior to assay and that a procedure 
blank is always included. This is impracticable where large 
numbers of samples are to be assayed, which is one of the big
advantages of RIA. However it has been shown that only about 40%
of PGI2 is metabolised to 6-keto-PGFloC (Myatt 1981) and little 
work has been published on the remaining 60% of metabolites such 
as 13,14-dihydro-6,15 diketo prostaglandin FloC. It is now 
generally accepted that to measure only one metabolite may give a 
false picture as for example with PGE2 . The term "prostacyclin
-  26 -
metabolite assay" may therefore be more accurate when using a 
polyclonal antibody. The term "metabolite assay" is routinely 
used in the measurement of other prostaglandins such as PGS^. 
We therefore decided to attempt to develop a method for a 
radioimmunoassay on unextracted plasma. Work published by Forder 
(1983) confirmed that direct assay methods could be of use 
provided only the linear portion of the standard displacement 
curve was used for measurement.
3.7 (a) (ii) Sensitivity
Although fairly high levels of plasma 64ceto-PGFloC are still 
being published it is now generally accepted that normal levels 
are in the low picogram range. Thus a very sensitive assay must
be developed in order to be able to measure these very low
levels. As will be shown in a later section of this chapter some
of the available commerical kits are not sufficiently sensitive 
for measuring plasma levels.
3.7 (b) Method of Sampling
It has been shown by Morris (1981) that variables in sampling 
procedure and preparation of samples can affect the results 
obtained from prostaglandin assays. A traumatic venepuncture may 
cause increased levels due to endothelial cell damage. It is now 
thought that white cells can produce PGl (Orlandi 1985) and
thus it is important that further in vitro generation of PGI^ 
after sampling is abolished. In our laboratory venous blood is 
collected using a 19 gauge butterfly needle. Blood is 
immediately put into cold plastic tubes containing 1:9 vol 3.8% 
trisodium citrate containing 3 x 10“^M indomethacin added to 
prevent in vitro generation of PGI2  and thromboxane.
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The tubes are kept in ice and centrifuged within one hour of 
sampling at 4 C and 2500g for fifteen minutes. The plasma is 
separated and stored in aliquots at -70°C until assay.
3.7 (c) Buffer
A wide range of buffers are used in RIA. The choice of buffer 
has been shown to make no difference to the assay provided it is 
within one unit of neutrality and has a molarity in the range 
0.01 - 0.1 (Chard 1981).
Care must also be taken to ensure that the buffer does not become 
contaminated by the ligand or by tracer. It is very easy to 
cause buffer contamination with pipette tips or other laboratory 
equipment and because levels being measured in this particular 
assay are so low it is easy to turn the buffer into a standard 
solution. Protein is commonly added to help to stabilise the
buffer and also to prevent absorption losses on to the surfaces 
of tubes, pipette tips or other equipment used in the assay. We 
use a O.IM phosphate buffer PH 7.0 containing 0.1% bovine albumin.
3.7 (d) Standards
The preparation of the standards for any assay is one of the most
important steps in ensuring the reliability of the results. The
ideal situation for any assay is to have a single standard for 
distribution to all laboratories concerned with a particular 
■ assay. The National Institute for Biological Standards is the
I principle agency in the United Kingdom for this purpose. However 
, to the present time no such international standard is available 
for 6-keto-PGFloC and each laboratory must prepare their own
f standards.
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The usual procedure for setting up a standard is to obtain a 
sufficiently large quantity of the substance in question and to 
dispense identical volumes of a known solution in several hundred 
tubes which can then be stored at low temperatures. Ideally each 
individual standard should be prepared independently from this 
stock solution rather than performing doubling dilutions where 
any error in an initial step will affect all subsequent steps. 
However in the case of 6-keto-PGFle^ where standards must be of 
such low concentrations practicality demands the use of doubling 
dilutions. Unless very large quantities of the original standard 
were available the preparation of individual standards would 
necessitate the measurement of such small volumes that the chance 
of error would be greater than with the doubling dilution 
method. However it is important that great care is taken when 
preparing each set of standards and appropriate controls are 
included in every assay as a check. We obtained a standard from 
Mr Simon Thomas, Medical Sciences Liaison Officer for the Upjohn 
Company. This standard was originally diluted in buffer to give 
a solution of Ing/ml, aliquots of which were stored at -70°C. 
Working dilutions as set out in the results section are prepared 
each week and these are stored at -4°C. A zero standard of 
buffer alone is stored under the same conditions as the other 
standards. As a control, a pool of normal plasma is collected in 
the same way as sample plasmas and aliquots are stored for up to 
six months and included with every assay.
3.7 (e) Labelled Ligand
In any binding assay there must be some means of determining the
final distribution between the bound and free fractions.
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In a radioimmunoassay this 'tracer' is a radioactive isotope. 
There are two types of tracer : those which have an existing atom 
in the ligand molecule replaced by a radioactive isotope of that 
atom for exanple for and those with an external label 
where an atom or atoms of a radioactive isotope such as ^^^i 
are substituted for an existing atom on the ligand molecule. 
Tnis type of external label is thus not identical to the 
unlabelled ligand, though in practice its behaviour should be 
undistinguishable from the unlabelled molecule. Tracers with an 
internal label are usually prepared on a commercial scale. 
Tritium labelled 6-kete-PGFl o& ( ^ H-6-keto-PGFloC ) was obtained 
from Amersham International and diluted with buffer as required.
3.7 (f) Antibody
Probably the most important component of any RIA is the antibody 
or binder which is used. The specificity of the antibody 
dictates how reliable the assay will be. The affinity of the 
antibody for the antigen is also important since this determines 
the energy of the reaction and the time taken to reach 
equilibrium. The production of an antibody of the required 
specificity with a high affinity or K value is a time consuming 
and problematical process. We were fortunate enough to receive a 
supply of antibody to 6-keto-PGFlo( from Dr Eric Preston, 
Department of Haematology, Royal Hallamshire Hospital, Sheffield. 
We also compared results using this antibody with results using 
other antibodies and this will be discussed later in chapter 3. 
Table 3.2 shows a list of the cross reactivities of the Sheffield 
antibody. With prostaglandin assays, where there are so many 
closely related compounds, it is very important to the
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specificity of the assay that any cross reactivity is as low as 
possible. Table 3.2 shows the cross reactivities of the 
Sheffield antibody.
Compound % cross reactivity
6-keto-PGF led 100.0
13.14-dihydro-6-keto-PGF l o t i.i
PGF^od 0.35
PGDg 0.25
PGF^oC 0.20
0.075
13.14-dihydro-6,15-diketo-PGFlal 0.075
6,15-diketo-PGF lod 0.075
13.14-dihydro-PGF 2 o i 0.020
PGAg 0.015
PGA^ 0.004
Thromboxane 0.004
13.14-dihydro-PGE^ 0.004
PGB^ 0.002
13.14-dihydro-PGE 0.001
13.14-dihydr0-15-k eto-PGF^oC 0.001
13.14-dihydro-15-keto-PGE^ 0.001
Arachidonic acid 0.001
Table 3.2 - Cross reactivities with available prostaglandins
3.7 (g) Separation Method
When the assay has reached equilibrium it is necessary to 
determine the distribution of the radioactive ligand between the 
bound and free fractions. A variety of techniques have been
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described for this purpose. The principal criteria for a 
separation procedure are efficiency and practicality. For 
exarrple electrophoresis (Hunter 1964) and gel column filtration 
(Haber 1965) have been described as techniques for separating 
bound and free fractions. However these techniques are very time 
consuming, especially where large numbers of samples are being 
assayed and are therefore i impracticable and rarely used 
nowadays. We tried fractional precipitation using polyethylene 
glycol. In terms of practicality this method is sinple, fast and 
inexpensive. The polyethylene glycol is added at a concentration 
in which the bound fraction is insoluble and therefore 
precipitates while the free fraction remains in solution. The 
precipitate is packed by centrifugation and the radioactivity of 
the supernatant (free fraction) can be counted. However we found 
that this method yielded a very high assay blank of about 15% on 
average and reproducibility was poor. This may be partly due to 
physical trapping of the tracer in the interstices of the bulky 
precipitate.
The double antibody technique of separation is now widely used 
especially where the second antibody is coupled to an insoluble 
matrix such as cellulose. The technique of double antibody 
separation methods was first described by Utiger (1962) and 
Morgan (1963). The second antibody is specific to the globulin 
of the species in which the first antibody was raised. This 
causes precipitation of the bound fraction which can once again 
be packed by centrifugation. We used "Sac-cel" cellulose coupled 
anti-rabbit antibody made by Wellcome Reagents, Beckenham, Kent. 
We were unable to obtain satisfactory separation using this 
method. The non-specific absorption of biological molecules to
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particle surfaces is widely used as a separation method. Figure
3.2 shows diagramatically the principle of the method. The most 
commonly used absorption material is charcoal which was first 
described by Herbert (1965). Originally it was recommended that 
the charcoal be pretreated with dextran to block any larger pores 
wnich might absorb the binder. However it has since been shown 
that this is unnecessary (BinoLtx 1973). By using free ligand 
only in the concentration used in our assay we showed that 300 jul 
of a 0.5% suspension of acid-washed charcoal (BDH) was sufficient 
to allow complete separation. It is important that the 
separation is performed using ice-cold charcoal and with the 
assay tubes in melting ice. This is important if absorption of 
the bound conplex is to be avoided.
For the same reason the time taken to perform the addition, 
mixing and centrifugation of tubes must be standardised. In our 
method the tubes are vortex mixed and centrifuged at exactly 9+^ 1 
minute from the addition of charcoal to the first tube. The 
tubes are centrifuged at 4°C for 10 minutes at 2500g. The 
supernatant is decanted into 10 mis scintillant (Packard 
Insta-Gel) and counted in a Packard scintillation counter (Model 
460, Packard Inc, USA).
3.7 (h) Performance of the Radioimmunoassay
Originally we set up an assay using the antibody at the 
recommended final dilution of 1:10,000. Using labelled ligand to 
give approximately 10000 cpm total counts and incubating the 
mixture for 18-20 hours at 4^C we were only able to achieve a 
detection limit of 50 pg/ml. Ihis did not bring our standard 
plasma within the limit of sensitivity of the assay.
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The most common method of increasing the sensitivity of an assay 
is to reduce the amount of tracer (Chard 1981). it is however 
wrong to assume that sensitivity can be increased indefinitely 
simply by reducing the amount of tracer. There is always a 
limiting concentration below which there is no significant 
increase in sensitivity. We set up a series of standard curves 
with standards varying from 2 . 0  pq/ml up to 1 0 0 0  pg/ml together 
with a sample of our standard pool plasma. We also added known 
amounts of 6 -keto-PGFloC and varied the amount of tracer used in 
each. The results are shown in Table 3,3.
Amount of Incubation STD plasma % Detn. limit
Tracer cpm time & temp (pg/ml) recovery (pg/ml)
10,000 Overnight 4 %  <50 6 8  50
7.000 " <50 93 50
/ 5,000 " <50 105 50
4.000 " <30 8 8  30
3.000 " <60 84 60
Table 3.3 - Results obtained vhen decreasing amounts of tracer 
were used
As can be seen we were unable to bring our standard plasma within 
the limits of sensitivity simply by reducing the amount of tracer 
used.
The use RIA's which are interrupted by separation of bound and 
free before equilibrium is reached is becoming more common with 
commercial kits. This can often appear to increase the 
sensitivity but may only be because the zero binding is reduced. 
We tried various incubation times and temperatures, but, as can 
be seen in Table 3.4 we were still unable to bring our standard 
plasma within the limits of detection of our assay.
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Amount of 
Tracer cpm
Incubation 
time 8t temp
2  hours 4^c
STD plasma % Detn. limit
(pg/ml) recovery (pg/ml)
10,000 
8,000 
6 ,000
3.000
6 . 0 0 0  1  hour 37%
3.000
20
50
50
40
30
30
70
75
88
80
42
60
20
50
50
40
30
30
Table 3.4 - Results obtained with various incubation times and 
temperatures
Normally reagents are added in the order sample - tracer - binder 
thus giving both labelled and unlabelled ligand equal access to 
the binding site. However it has been shown by complicated 
mathematical analysis (Samols 1963) that if the order is changed 
to sample - binder - tracer and if the addition of the tracer is 
delayed, sensitivity may be increased. However we were unable to 
increase the sensitivity of our assay using this ' late-addition' 
method.
It has been shown that reducing the amount of binder used can 
increase the sensitivity of an assay (Chard 1981). There must 
however be a balance between the apparent increase in sensitivity 
and the confidence limits of replicates. Where the zero binding 
falls below 2 0 % any apparent increase in sensitivity is negated 
by the decrease in precision. We reduced the final concentration 
of our antibody to 1:35000 using tracer of 2-3000 cpm. By
increasing our incubation time we were able to increase our
sensitivity to 1 0  pg/ml thus bringing our standard plasma within
the limits of sensitivity of the assay. It can be seen from
figure 3.3 that by increasing the incubation time to 48 hours in 
order to allow our assay to reach equilibrium we were able to 
obtain zero binding of greater than 60%.
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The method used therefore is to mix 20^1 of standard or sanple, 
lOOjal tracer to give approx 2-300Ocpm and 5(ÿjl antibody giving a 
final dilution of 1:35000. The mixture is incubated for 48 hours 
at 4°C and then separation of bound and free is achieved using 
charcoal as described. The exact protocol for the assay is shown 
in Table 3.5. Standards of 2 , 3.9, 7.8, 15.6, 31.25, 62.5, 125, 
250, 500 and 1000 pg/ml are used.
Tube
Non specific Stds 
Total binding 0-1000
Count Buffer Plasma pg/ml Std plasma Sample
Buffer
Standard
Plasma
Standard 
or sample
3H PGFl 
Antibody
250 250 50
200
100 100 100
200
100
50
200
100
50
200
100
50
Mix and incubate for 48 hours at 4 %
Buffer
Charcoal
Suspension
300ul
300 300 300 300 300
Spin at exactly 9 + 1  minute after start of charcoal addition and 
centrifuge at 4°C and 2500 g for 10 minutes. Decant supernatant 
into 1 0  ml scintillant and count.
Table 3.5 - Protocol for RIA of PGI^ metabolites (all volumes injil)
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3.7 (i) Results
Figure 3.4 shows the standard curves obtained over ten assays 
using the method described. The horizontal axis shows the 
concentration of 6 -keto-PGFloC used in the standards and the 
vertical axis the percentage binding with the zero binding taken 
as 1 0 0 %.
Taking the limit of sensitivitiy as being two standard deviations 
from zero binding the lower limit of sensitivity for the assay is 
10 pg/ml. It should be noted however that this is the average 
figure for sensitivity. The minimal detection limit of any 
radioimmunoassay is likely to vary from one assay to another and 
also from one operator to another. If the replicates for the 
zero standard are poor the lower limit of sensitivity may be 
greatly increased. Conversely the sensitivity will increase with 
greater precision.
Over ten assays the inter and intra assay variation for the 
method is 4.9 and 4% respectively.
The mean recovery over ten assays of added known amounts of 
6 -keto-PGFl oCis 95 + 9% (SD). The normal range for the assay 
is 10 to 22 pg/ml (x = 13.1 pg/ml).
3.7 (j) Validation of Assay
In order to validate our assay by showing that we are measuring 
PGI2  metabolites, we allowed known quantities of PGI2  
(Wellcome Laboratories) to hydrolyse at 37°C for 30 minutes in 
phosphate buffer pH 7.0. Figure 3.5 shows the curves obtained. 
The curves show parallelism over the linear portion of the curve 
showing that the difference between the two materials is solely 
in their affinity for the antibody.
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Parallelism should also be demonstrated by diluting an unknown 
sample several times and measuring these dilutions against the
standard curve. After multiplication by the dilution factor all 
dilutions should give a similar value.
However due to the low normal levels of PGIg metabolites in 
plasma this is not usually possible. However this has been done 
with plasma from a patient receiving an infusion of PGI^ and
the results obtained are shown in Table 3.6.
PGI2  metabolite
Dilution value (pg/ml)
Undiluted 170
1 / 2  81
1/4 38
Table 3.6 - PGI9 metabolite levels on diluted sample
We also have validated the assay by adding known amounts of 
6 -keto-PGFlo6  to our standard pool plasma. As already shown in 
the results section 3.7(i), the mean recovery was 95 +9% (SD).
As another means of validating our assay we gave an infusion of 
PGIg to a normal volunteer. Blood was sanpled by separate
venepunctures at each of the times shown. The samples were
processed as previously described and the plasma assayed. 
Results obtained are shown in Table 3.7.
time Dose of PGI9  (jug) PGI9  metabolites (pg/ml)
0  0 5
15 4 50
30 8  70
45 12 139
60 16 2 2 0
15 min post- 0 5
infusion
Table 3.7 - Metabolite concentrations during infusions of PGI9
Ihis shows that as the dose of PGI^ was increased the levels of 
plasma PGIg metabolites increased correspondingly.
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3 . 8  Comparison of ^H-6 -Keto-PGFloCand 6 -keto-PGFlo^
Higher specific activity can be obtained with an iodinated label 
compared to a tritiated label. We were able to obtain a 
commercial kit (N.E.N.) which used an iodinated label for the 
measurement of 6 -keto-PGFlo^ . Initially we used the protocol 
described for the kit and, as with our initial assays, found that 
the limit of sensitivity of the assay did not bring our standard 
plasma within measurable limits. However we modified the method 
by using half the amount of antibody - 5Oui instead of IGGul per 
tube and half the amount of label. As with our own method we 
increased the incubation time to 48 hours. As can be seen in 
figure 3.6 we were able to obtain a more sensitive assay, with 
slightly better sensitivity than when using tritiated tracer. 
This however is the result of only one assay using this iodinated 
tracer, and as can be seen from figure 3.6 the assay was not much 
more sensitive than our own method. Unfortunately because of the 
very high cost of the kit we were unable to perform any
validation experiments with it. For the same reason the
sensitivity of the method was based on only one assay and may
have inproved on subsequent occasions. However if any assay is 
, to be viable in a clinical situation cost must be a prime
' consideration. Any increase in sensitivity would not be worth 
the considerably higher cost per sample.
3.9 Results using different antibodies
Viinikka and Ylikorkala have shown that 6 -keto-PGFlod assays 
performed with two antibodies of apparently similar specificity 
gave different results (Viinikka 1982). Ihis may have been due 
to some so far undiscovered closely related compound cross
reacting with only one of these antibodies.
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We tested antibodies from several different sources. We used our 
own methodology with these antibodies all of which had very 
similar cross reactivities. Results are shown in Table 3.8.
Source of Antibody Tracer Standard plasma (pg/ml)
Walker Laboratories 125i 1 2
New England Nuclear " 11.5
Upjohn Company 3H 10
Bioanalysis " 9
Walker Laboratories " 8
Table 3.8 - Results using different antibodies
As can be seen the results varied little from the value of 11.2 
+ 1.7 pg/ml for the standard pool plasma using our original 
antibody. As all these figures are the results from only one 
assay they cannot be compared exactly with our own value which 
was the mean of ten assays. However there is no evidence of any 
significant difference as has been observed by Viinikka.
3.10 Prostacyclin Stimulating Factor
3.10 (a) Introduction
PGI2  is the most potent inhibitor of platelet aggregation yet 
discovered. Its production by the vascular endothelium is 
thought to be one mechanism by which the vessel wall maintains a 
patency (Moncada 1976, Gryglewski 1976). In vitro cultures of 
' vascular endothelial cells synthesise and release PGI^ which 
can then be measured by RIA (Weksler 1977, McIntyre 1978). 
Several researchers have reported the existence of factors in 
plasma which might regulate the production of PGI^ by the 
vascular endothelium (McIntyre 1978, Reimzzi 1979 a, 
Defreyn 1980).
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A marked decrease in this stimulation factor has been found in 
the haemolytic ureamic syndrome (Remuzzi 1978 b); immediately 
after actue myocardial infarction (Yui 1984) and in sickle cell 
anaemia (Stuart 1981). Much of the work done trying to measure 
this PGI^ stimulating factor has used rat aortic rings which 
' are exhausted of spontaneous PGI^ production and then 
stimulated to produce PGI^ once more (Yui 1984, Jorgensen 1981, 
Remuzzi 1979). However the use of human tissue would seem to be 
preferable and therefore we have developed a method which uses 
human umbilical artery rings.
3.10 (b) Method
Human umbilical cords are obtained from normal term deliveries. 
Ihe cords are immediately placed in ice cold Ringer's buffer. 
Within two hours of delivery the arteries are dissected free from 
the surrounding tissue and cut into approximately 1 mm rings. The 
rings are incubated at 37°C for 30 minutes in Ringer's buffer 
and the buffer is then renewed. This process is repeated until 
no antiaggregatory activity is detectable in the supernatant. 
This is tested by adding 100 jul of supernatant to 200 jul platelet 
rich plasma (PRP) in the cuvette of an aggregometer (Malin 
Electronics, Green Street, Ayr).
Aggregation is induced by adding 2 uj/ml collagen. Approximately 
15 mg (wet weight) aliquots of these exhausted rings are then 
placed in plastic tubes with 1 ml Ringer's buffer and placed in 
melting ice. Rings from different arteries must be kept seperate 
and tested individually for 'exhaustion'. Ringer's buffer is 
removed from one aliquot of rings and replaced by 1  ml of normal 
pool plasma collected from 1 0  male and 1 0  female donors, the
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blood being anticoagulated (1:9) with 3.2% trisodium citrate. 
The rings and plasma are incubated at 37°C and 100 jul aliquots 
removed at five minute intervals. This is added to 200 jul PRP in 
the aggregometer and collagen 2 jag/ml added. The experiment is 
then repeated on an aliquot of rings from the same artery using 
sample plasma. In each experiment, as a control, 100 j i l  of
either pool or sample plasma which has not been incubated with 
artery rings is added to the PRP and aggregation induced as
before. The inhibition of aggregation shown by the plasma
incubated with rings is expressed as a percentage of this control 
value.
Some researchers have shown that serum causes greater stimulation 
of PGI2  release than plasma (Ritter 1983, Seid 1983) whereas 
other workers failed to find this (Vergara:-Dauden 1985). We
therefore performed similar experiments incubating the rings with 
serum in place of platelet poor plasma.
The principle of the assay method is shown diagramatically in 
figure 3.7.
3.10 (c) Results
The results obtained incubating umbilical artery rings with 
normal platelet poor plasma for increasing lengths of time are 
shown in figure 3.8(a).
The results obtained in similar experiments using normal serum 
instead of platelet poor plasma are shown in figure 3.8(b).
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200;il P.R.P. + 10(^1 supernatant 
buffer incubated with umbilical 
artery rings for 5 minutes
COLLAGEN
ADDED
(ii) 200jnl P.R.P. + 100^1 buffer
COLLAGEN
ADDED
(iii) 200^1 P.R.P. + 10(^1 pool 
P.P.P.
COLLAGEN
ADDED
(iv) 20Qwl P.R.P. + lOQul 
supernatant pool P.P.P. 
incubated with umbilical 
artery rings for 5 minutes
COLLAGEN
ADDED
COLLAGEN
ADDED
(v) 200^1 P.R.P. + lOQial supernatant
pool P.P.P. incubated with 
umbilical artery rings for 
10 minutes
%
COLLAGEN
ADDED
(vi) 2 0 0 ji l P.R.P. + lOC^l supernatant
pool P.P.P. incubated with umbilical 
artery rings for 15 minutes
(vii) 200pl P.R.P. + lOO/il supernatant 
pool P.P.P. incubated with 
umbilical artery rings for 
20 minutes
COLLAGEN
ADDED
COLLAGEN
ADDED
(viii) 200^1 P.R.P. + 100^1 supernatant 
pool P.P.P. incubated with 
umbilical artery rings for 
30 minutes
200 jà l P.R.P. + lOC^l supernatant 
buffer incubated with umbilical 
artery rings for 5 minutes
COLLAGEN
ADDED
(ii) 200pl P.R.P. + lOOjil normal
serum
COLLAGEN
ADDED
(iii) 200pl P.R.P. + lO O jil buffer
COLLAGEN
ADDED
20(^1 P.R.P. + lOO^ ii supernatant 
serum incubated with umbilical artery 
rings for 5 minutes
COLLAGEN
ADDED
COLLAGEN 
DED
(v) 200pl P.R.P. + lOQ/ul supernatant
serum incubated with umbilical 
artery rings for 10 minutes
200pl P.R.P. + lOOpl supernatant 
serum incubated with umbilical 
artery rings for 15 minutes
COLLAGEN
ADDED
irTÜURE j.W (Jd )
(vii) 2 0 0 ji l P.R.P. + 10(^1 supernatant 
serum incubated with umbilical 
artery rings for 20 minutes
COLLAGEN
ADDED
(viii
COLLAGEN
ADDED
200pl P.R.P. + 10(^1 
supernatant serum incubated 
with umbilical artery rings 
for 30 minutes
3.10 (d) Discussion
These results show that when platelet rich plasma is 
incubated with umbilical artery rings for only five minutes 
aggregation is completely inhibited and this effect is still 
present after 30 minutes incubation. When serum from a
normal female was used in place of platelet poor plasma
aggregation was not completely inhibited until 30 minutes 
incubation time. We therefore found that both normal
platelet poor plasma and serum inhibited aggregation 
completely, but serum required incubation with the artery 
rings for a considerably longer period of time than did 
plasma for this effect to be observed. We obtained similar 
results using serum from another normal female donor. 
However since the platelet poor plasma used was from a pool 
of normal plasma obtained from 1 0  male and 1 0  female
volunteers the results could possibly be different if a pool 
serum was used.
3.11 Umbilical Artery Perfusion Model
3.11 (a) Introduction
The use of rat aortic rings to measure PGI^ production by 
endothelial cells (Yui 1984, Jorgensen 1981) has been well 
documented. Our method using umbilical artery rings showed 
inhibition of platelet aggregation from normal plasma which had 
been incubated with artery rings. However these methods have 
certain disadvantages. Firstly, as previously discussed, the use 
of human tissue would seem to be preferable to rat aortic rings. 
Even when using human umbilical artery rings there are still 
disadvantages. Layers of subendothelium are exposed using artery
rings and because the entire surface area of endothelium in the
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experiment is so small these subendothelial layers could play a 
significant part. It has been shown (Serneri 1983) that the 
medial layers of arteries are capable of producing thromboxane. 
As this has directly opposing actions to PGI^ it could 
influence the results of the experiments. It is also almost 
' inevitable that endothelial cells are lost from the artery rings 
during repeated washings. This may not be a constant loss from 
one aliquot to the next and therefore this also could influence 
the results. During preparation of the rings the tissue is also 
severely traumatised and it has been shown (Mehta 1982 a) that 
mechanical trauma may result in the release of TXA^ from intact 
human umbilical vein though in much lesser quantities than 
PGIg. Vessel ring models also lack the pulsatile flow of 
normal circulation. As the aim of any in vitro model is to 
resemble the in vivo situation as closely as possible we decided 
to try to develop an in vitro model which would resemble the in 
vivo situation more closely. Other researchers have used 
continuously perfused umbilical vein models (Mehta 1982 a, Mehta 
1982 b). However it has been shown that arterial tissue is 
capable of producing more PGI2  than venous tissue (Kent 1981).
’ We have therefore developed an umbilical artery perfusion model
!
, to measure endothelial cell PGI^ production.
3.11 (b) Materials and Methods
We use umbilical cords from normal term deliveries which have not 
been subjected to trauma, the placenta being delivered by 
maternal effort. Cords from elective sections at term are 
also used.
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The cords are detached from the placenta and immediately placed 
in Ringer's buffer at 4°C. In our original experiments we used 
the complete cord, cannulating one artery within 2 - 3  hours of 
. delivery. The artery was continuously perfused and fractions 
collected for measurement of PGl^ metabolites by 
radioimmunoassay (R.I.A.). However using the whole cord we found 
large variations between individual cords of equal length and 
also between two halves of the same cord as shown in figure 
3.10. This may be due to different surface area of endothelium 
in equal lengths of cord caused by twisting of the cord. Another 
disadvantage of this method was that about four/fifths of the
' cords used were unsuitable due to extravasation of the perfusate
I
1 into the surrounding tissue; this being not always immediately 
visible. We now use a dissected vessel model. The artery is 
carefully dissected free from the surrounding Wharton's jelly and 
is then cannulated with a size 16 Medicut cannula and flushed 
through with buffer to clear any residual blood.
The vessel is cut into two equal halves, one half acting as 
control, and is supported in a bath of oxygenated Ringer's buffer 
I at 37°C. Each half is connected to a peristaltic punp which 
gives a pulsatile flow similar to normal circulation. The punps 
are calibrated to deliver a flow of 1 ml per minute. One half of 
the cord is perfused with oxygenated Ringer's buffer to act as 
control while the other half is perfused with drug or plasma as 
required. 5ml fractions are collected using a fraction collector 
and stored at -70° for assay for PGl^ metabolites using 
R.I.A. as described in 3.7. Figure 3.11 shows a photograph of 
the apparatus used.
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Figure 3.11 - Hie apparatus used
To show that we had healthy, functioning endothelium we perfused 
one artery with whole blood followed by 1 % glutaraldehyde in 
buffer as fixative. This was then prepared for scanning electron 
microscopy by dehydration and critical point drying. Hie 
experiment was performed on two halves oC the same vessel: the 
first after perfusion with 50 ml of buffer and the second after 
overnight perfusion.
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3.11 (c) Results
The electron micrograph scans show that in the first case where 
the vessel had been perfused with only 50 ml of buffer there is 
healthy endothelium and no visible platelet clumps (Fig 3.12).
u
Figure 3.12 - Electron micrograph prior to exhaustion (x 2500)
- 47 -
However after overnight perfusion there are large platelet 
aggregates visible (Figure 3.13) after exhaustion of PGI2  
production.
Figure 3.13 - Electron micrograph post exhaustion (x 2500)
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Figure 3.14 shows a graph of PGI2 M levels from two halves of 
the same artery perfused simultaneously with Ringer's buffer. 
After perfusion of approximately 150 ml (150 minutes) levels of
I PGI^ metabolites reached a steady baseline level of 100 
pg/ml. There is a correlation of 0.95 between levels of PGI2  
metabolites in the two halves of the vessel.
/ We also wanted to show that PG12 production could be inhibited.
j We were able to show inhibition both with aspirin 250 jug/ml
1 ' .
(Figure 3.15) and indomethacin 1 pg/ml (Figure 3.16).
It was also important to show that our endothelium could be
stimulated to produce more PGl^ after reaching a steady
baseline level. In order to show this we used platelet poor
plasma which has been shown to contain a factor or factors
capable of stimulating endothelial cell PGI2  production
(McIntyre 1978, Remuzzi 1979 a, Defreyn 1980). After perfusing
both halves of the same artery with Ringer's buffer until a
steady baseline level was reached we perfused one half with 5ml
of normal pool platelet poor plasma and continued to perfuse the
other half with buffer. As can be seen in Figure 3.17 levels of
PGI2  metabolites rose in the half perfused with plasma while
the control levels remained steady.
3.11 (d) Discussion
Using this dissected umbilical artery model we have shown, by the 
use of electron microscopy, that we have healthy functioning 
f endothelium. Using normal platelet poor plasma we have shown 
that it is capable of stimulation to produce more PGI2  after 
having reached a steady baseline level. We have also shown that 
PGI2  production can be inhibited both by aspirin and by
indomethacin.
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Although the flow rate and pressure are less than in the in vivo 
situation we feel that our model resembles the in vivo situation 
more closely than models using artery rings. There is also the 
advantage that umbilical cords are ready available. We feel that 
it is a useful model to assess the effects of drugs on PGI^ 
production. Although it would be impracticable to use this model 
to assay large numbers of samples for PGI^ stimulating factor 
it would be useful to test plasma samples which were found to 
have low PGI2  stimulating factor using the ring model. We also 
hope to be able to use this model to see if there is decreased 
endothelial cell PG% 2  production in cords obtained from mothers 
with pregnancy induced hypertension. It has also recently been 
shown that PG% 2  production was decreased in the umbilical 
artery from a mother who delivered a baby with Down's syndrome 
(Makila 1985). Decreased PGI2  production has also been shown 
in smoking mothers (Dadak 1982) and may be a factor for reduced 
foetal placental blood flow or foetal growth retardation. Our 
model may be a useful tool in the further elucidation of these 
conditions.
CHAPTER 4 - MEASUREMENT OF THROMBOXANE
4.1 Introduction
As with PGI^, much research has been carried out to try to
determine what the role of thromboxane is in health and disease. 
Since its discovery (Piper 1969) various methods of quantifying 
thromboxane have been developed. Because of the very short half 
life of TXA^ many of these techniques use TXBg, the stable 
breakdown product ^ as an index of TXA^ production. In this 
chapter the various methods will be described and advantages and 
disadvantages discussed.
4.2 Bioassay
Ihe ability of TXA^ to contract vascular smooth muscle which 
first led to its discovery is still used as a bioassay
technique. The ability of TXA^ to cause aggregation of
platelets may also be used to detect thromboxane-like activity. 
However the very short half-life of only 36 seconds in aqueous 
media causes much difficulty when using either of these methods 
of detection. As TXB^, the stable breakdown product^ has only 
very weak biological activity bioassay techniques are not 
suitable for its measurement. The disadvantage of bioassay of
thromboxane therefore, as well as those discussed previously in 
3.2,is mainly its very short half life.
4.3 Gas chromotoqraphy mass spectometry
TXB_ was shown to be the stable hydrolysis product of TXA 
2 ^
using electron impact mass spectometry (Hamberg 1975).
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The urinary metabolites of infused TXB in man were identified 
by gas chromotography - electron impact mass spectometry (Roberts 
1981) which in turn led to the development of quantitative assays 
for TXB2  based on analysis of a urinary metabolite (Fitzgerald
1983). However when measuring plasma levels of TXB2 , RIA is 
the method most commonly used. The disadvantages of GCMS as 
discussed in 3.3 for PGI2  apply also to thromboxane.
4.4 Radioimmunoassay
4.4 (a) Introduction
One of the first RIA's for TXB2  was developed by Granstrdm and 
colleagues (Granstrdm 1978) and since then RIA's for TXB2  have 
been developed by many other groups (Viinikka 1980, Mitchell 
1978, Kaar 1983, Orlandi 1983, Lieb 1983). Unlike plasma 
6-keto-PGFl od the range of reported normal values has not been so
great as is shown in Table 4.1.
Plasma TXB? Author
(pg/ml)
70.1 + 26.7 Viinikka 1980
276 + 80.2 (age 19.9 + 4.1 yrs) Kaar 1983
118 Ouwendijk 1983
101 + 34.4 (age 11.7 + 3.8 yrs) Orlandi 1983
64.2 + 29.4 Lieb 1983
Table 4.1 - Range of reported normal levels of plasma TXB2
The arguments for and against extraction of samples prior to 
R.I.A. as discussed in 3.7(a) in relation to 6-keto-PGFloCapply 
equally to TXB2 . The measurement of plasma levels of TXB2  
has also received much criticism due to the potential for
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artefactually high levels. Since TXA_ is generated by 
platelets, any trauma associated with venepuncture will activate 
the platelets and so give rise to artificially high levels. 
Unless an inhibitor of TXA^ generation is added to the 
anticoagulant there will also be a further generation of 
thromboxane by the platelets during processing of the sanple. 
However provided a standard venepuncture technique is adopted and 
samples discarded where there was difficulty experienced in 
obtaining blood, the in vitro generation of TXA^ should be 
minimised. The processing and handling of samples must also be 
carefully standardised for the same reason.
4.4 (b) Sampling procedure
Venous blood is collected using a 19 gauge butterfly needle. 
Samples are discarded where there is any trauma associated with 
the venepuncture. The blood is placed immediately into ice cold 
plastic tubes containing 1:9 vol/vol 3.8% sodium citrate with
-5
indomethacin added to give a final concentration of 3 x 10 m 
to prevent in vitro generation of TXA^. The sanples are kept 
on ice and centrifuged within one hour at 250Og and 4^C for 15 
minutes. The plasma is stored in aliquots at -70*^ C until 
assay. We have conpared results obtained using different 
sampling techniques:
(i) Citrate/indomethacin anticoagulant in the syringe and 
blood collected directly into this.
(ii) Adding UK 38,485 (Pfizer Ltd) a thromboxane synthetase 
inhibitor to the anticoagulant instead of indomethacin.
The results of these experiments are shown in table 4.2.
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Mean TXB (pg/ml) Method Method Original
(SD) (i) (ii) Method
n=6 95+16.4 102.7+18.6 85.2+9.8
Table 4.2 - Results obtained using different sanpling techniques
4.4 (c) Radioimmunoassay Procedure
Antibody to TXB^ and TXB^ for use in making up standards were 
gifted by Mr Simon Thomas, Medical Science Liaison Officer, 
Upjohn Ltd, Crawley. The same criteria as discussed in 3.7(d) 
for the preparation of standards for 6-keto-PGFl oC were 
observed. The standard obtained was diluted in assay buffer to 
give a stock solution of Ing/ml. Aliquots of this standard are 
stored at -70^C together with aliquots of a zero standard as 
for 6-keto-PGFl . Working dilutions ranging from 3.9 to 1000 
pg/ml are prepared freshly each week and stored at 4^C. The 
pool of normal plasma used as a standard for PGI^ metabolites 
is also used for TXB^. labelled TXB2  was obtained from
Amersham International (Amersham, Buckinghamshire). The method 
used for the RIA is exactly as described for the antibody by F A 
Fitzpatrick of the Drug Metabolism Research Department, Upjohn 
Company Ltd, Kalamazoo, except that we use the same buffer as for 
the PGI2  metabolite assay. To appropriately labelled tubes 
(Luckham LP^) are added lOOpl standard or sample, lOQul 
TXB2  to give total counts of approximately 3000cpm and lOQjal 
antibody (final dulition 1:10,000). Both plasma and buffer 
non-specific binding are determined using pool plasma or the 
highest standard respectively. Ihe tubes are incubated for 20-24 
hours at 4°C. After incubation the tubes are placed in a bath 
of melting ice and 300/il of 0.5% acid washed charcoal (BDH) in
buffer is added to all except total count tubes.
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All tubes are centrifuged at exactly 9 + 1 minute from the start 
of addition of charcoal at 4°C and 2500g for 10 minutes. The 
tubes are replaced in the ice bath and the supernatant decanted 
into 10 mis scintillant (Packard Insta Gel) and counted in a 
Packard scintillation counter.
The exact protocol for the assay is shown in Table 4.3.
Tube
Buffer
Standard
Plasma
Standard 
or sample
3H TXB2
Antibody
Total
Count
200
100
Non specific Stds
binding 0-1000
Buffer Plasma pg/ml
100 100
100
100
100 100
100
100
100
Std
plasma
100
100
100
Sample
100
100
100
Mix well and incubate at 4°C for 20-24 hours
Buffer
Charcoal
Suspension
300
300 300 300 300 300
Centrifuge at exactly 9 + 1  minute after start of additional of 
charcoal at 4°C and 2500 rpm for 10 minutes. Decant supernatant 
into lOmls scintillant and count.
Table 4.3 - Protocol for TXB assay (all volumes injUl)
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4.4 (d) Results
Figure 4.1 shows the results for the standard curve obtained over 
ten assays using the method described. The horizontal axis shows 
the concentration of TXB^ in the standards and the vertical 
axis the percentage binding taking zero binding to be 100%.
Taking the limit of sensitivity as being two standard deviations 
from zero binding the average lower limit of sensitivity for each 
assay is 15.6 pg/ml.
Over ten assays the inter and intra assay variations are 10% and 
4% respectively.
4.5 Serum Thromboxane Measurement
4.5 (a) Introduction
Because of methodological difficulties in blood sampling when 
measuring plasma TXB^ as discussed in 4.4(a), thrombin-induced 
TXA^ production in whole blood, as reflected by serum TXB^ 
measurements, is becoming widespread for human studies in health 
and disease. The method described here employs an endogenous 
stimulus i.e. generated thrombin to platelets in whole blood. 
Thrombin induced TXA^ production in whole blood appears to 
accurately reflect the inhibition of platelet TXA^ biosynthesis 
by cyclooxygenase inhibitors in vivo (Patrignani et al 1982, 
Weksler et al 1983) and by thromboxane synthetase inhibitors 
(Fischer et al 1983, Patrignan et al 1984). As the volume of 
blood required is much less than for measurements of plasma 
TXB^ this allows for long term studies on the same subject with 
negligible blood loss. The final measurement of serum TXB2  
levels is performed using the R.I.A. previously described in 4.3.
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However the handling of the blood sample prior to incubation at 
o
37 C may be the cause of variations in reported normal values 
(Mahoney et al 1983, Codde et al 1984). Because of this we 
looked initially at the effects of incubation of the blood at 
different temperatures and for different lengths of time on the 
serum TXB^ levels.
4.5 (b) Method
Venous blood was taken from healthy volunteers who had taken no 
drugs over the previous two weeks. Venepuncture was carried out 
using a 19 gauge butterfly needle with minimal venous 
compression. The blood was immediately divided into 1ml aliquots 
and placed in glass tubes and these were allowed to stand at room 
temperature (approximately 24°C) for different lengths of time 
i.e. 10, 30, 60, 90 and 120 minutes. Thereafter the blood was 
incubated in a constant temperature room at 37°C for a standard 
one hour period. The tubes were then centrifuged at 2500g for 15 
minutes to separate the serum which was stored at -70^C. In a 
second series of experiments blood from the same volunteers was 
taken and the aliquots were immediately incubated at 37°C for 
varying times i.e. 60, 90, 120 and 150 minutes. The serum was 
prepared as before, and was assayed in duplicate for TXBg using 
R.I.A. as previously described.
4.5 (c) Results
As can be seen from Table 4.4 there was a statistically
2
significant fall in the recorded values of serum TXB with 
increasing standing time at room temperature (correlation 0.89).
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Prior to 1 hr at 37^C (X + S,.E.M.
0 179.6 + 13.8
30 90.0 + 7.0
60 56.8 + 3.5
90 45.6 + 3.0
120 39.2 + 1.8
Table 4.4 - Serum levels of TXB^ with increasing standing 
time at room temperature prior to incubation 
for one hour at 37^C
Table 4.5 shows the results when the samples were incubated 
immediately after venepuncture but left for varying times at 
37°C.
Time at 37°C TXB? (ng/ml) x + S.E.M. n = 10
A 60 176.5+16.0
B 90 112 + 5.7 *
C 120 103 + 8.2
D 150 119.5+5.7
* Different from A p 0.05 
Table 4.5 - Serum TXB^ levels with increasing time of 
incubation at 37°C
This shows a statisically significant decrease in recorded TXB^ 
levels between 60 and 90 minutes incubation but no statistical 
difference thereafter. Our normal range of serum TXB2  levels 
when samples are placed immediately into a temperature of 37^C 
and left to incubate for one hour is from 156 - 400 ng/ml with
a mean of 311 _+ 112 (S.D.) ng/ml.
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4.5 (d) Discussion
These results agree with work done by Patrono (1980) but also 
show that more important than the actual incubation time is the 
time the sample is left at room temperature prior to incubation 
at 37^C. Even if blood is left to stand at room tenperature 
for 30 minutes prior to incubation at 37°C levels fall by 50%. 
Our results agree with work done by Hall and colleagues (Hall
1984). They conclude that since platelet rich plasma can be kept 
at 37^C for several hours and still have the ability to produce 
TXB^ from arachidonate at 37°C the reduction in TXB^ after 
I standing room at temperature is probably not due to instability 
of the enzyme. However whether or not PRP still retains this 
ability after standing at room temperature rather than 37°C has 
still to be determined.
Much more work would require to be carried out in order to
demonstrate the exact mechanism for this phenomena. However from
the practical point of view this means that it is imperative
that, immediately after withdrawal, blood is incubated at
37^C. Therefore if blood sampling is performed outwith the
laboratory for example in wards or at clinics there must be
facilities available for immediate transfer of sanples to a
I temperature of 37°C. For this purpose we use a protable water
bath. Provided care is taken in the handling of the samples in
the way described, serum TXB^ levels would seem to give a
reliable measurement of the ability of platelets to generate
thromboxane in response to an endogenous stimulus. This may be
of more relevance than circulating levels as measured by plasma
TXB_. Some patients may generate very high amounts of TXA 
2 ^
in response to stimuli and this may predispose them to a
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thrombotic tendency. Conversely patients with certain bleeding 
disorders may have an inpaired ability to generate thromboxane. 
This will be discussed in a chapter 7.
4.6 Thromboxane Generation
4.6 (a) Introduction
The measurement of serum throxboxane levels measures the 
generation of TXA^ by platelets in response to an endogenous 
stimulation: thrombin generated during blood clotting. We have 
also examined thromboxane generation in response to an exogenous 
stimulus: collagen, added at a final dilution of 4ug/ml.
4.6 (b) Method
Platelet rich plasma (PRP) is prepared by centrifugation of whole 
blood at 180g for 10 minutes. The platelet count if greater than
Q Q
400 X 10 /litre is adjusted to approximately 300x 10 /litre
with the same platelet poor plasma. 200jjl of PRP are placed in
the cuvette of an aggregometer (Malin Electronics) at 37^C and 
aggregation induced by the addition of collagen (Hormon-Chemie, 
Munich) at a final concentration of 4 jug/ml using the method of 
Born (1962). ADP at a final concentration of 4^m may also be 
used. Aggregation is allowed to continue with constant stirring 
for exactly 4 minutes. The reaction is then terminated by the 
addition of 200>il of absolute alcohol. The samples are stored at 
-70^C until RIA for TXB^. Prior to assay the sanples are 
thawed and centrifuged at 2500g for 15 minutes. The supernatant 
is removed and diluted 1/400 with assay buffer.
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4.6 (c) Results
Figure 4.2 shows the dose response curve we obtained using 
various concentrations of collagen.
Figure 4.3 shows the dose response curve obtained using various 
concentrations of ADP.
I In order to demonstrate inhibition of Tx generation using this 
method we incubated PRP for five minutes with indomethacin prior 
to addition of collagen 4 jag/ml. The results obtained are shown 
in Table 4.6.
Concentration 
of indomethacin TXB (ng/ml)
Control (n = 6) 96+9.8
Indomethacin 100 ng/ml 99.3 23.0
Indomethacin 1 jug/ml 5.4 + 3.2
Table 4.6 - TX generation after prior incubation with
indomethacin
Our normal range for thromboxane generation using 4jig/ml collagen 
is 80-180 ng/ml with a mean of 118 + 30 ng/ml (SD).
4.7 Thromboxane generation in Bleeding Time Blood
4.7 (a) Introduction
Some familial bleeding disorders have been associated with 
deficiencies in the synthesis of thromboxane A^ by platelets 
(Defreyn 1981). The presence of TXA^ in circulating blood as 
measured by plasma TXB^ levels is perhaps of less relevance in 
these disorders than serum TXB2  levels or thromboxane
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FIGURE 4.3 : THROMBOXANE GENERATION DOSE
RESPONSE CURVE FOR ADP
generation in response to an exogenous stimulus as described in 
4.6. We thought that it would be of interest to be able to get 
some indication of amount of TXA generated at the site of 
injury. There have been studies on the measurement of TXA^ 
generation from bleeding time blood by Thorngren (1983). 
Although work done by Kakkar (1981) suggests that normally TXA 
plays only a minor role in haemostasis it may be important where 
there is a bleeding tendency. As a significant part of the work 
in our department is concerned with bleeding disorders we felt 
that a method to measure TXA^ production in bleeding time blood 
would be of use when used in conjunction with the other 
measurements of TXA^ production already described in this 
chapter. Thorngren (1983) collected the blood at intervals of 
one minute from the skin incision. The blood was collected into 
capillary tubes anticoagulated with EDTA and indomethacin. We 
attempted this method but found that the volume of blood was so 
small that there was insufficient plasma after centrifugation to 
enable a plasma assay to be performed reliably. Another problem 
was in obtaining a constant volume of blood at each sampling 
which is important because of the standard amount of 
anticoagulant in each tube.
4.7 (b) Method
The bleeding time is measured using a simplate II bleeding time 
device (General Diagnostics, Science Park, Milton Road, 
Cambridge). The blood from one incision is used to measure the 
bleeding time in the usual way. The blood from the second 
incision is collected at intervals of one minute into capillary
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blood sampling tubes (Sarstedt, Boston Road, Leicester). The
tubes are immediately placed in a water bath at 37°C and left
to incubate for one hour. The samples are centrifuged at 2500g 
for 15 minutes and the supernatant serum diluted 1/400 with assay 
buffer. The diluted serum is mixed and stored at -70°C until 
RIA for TXB^. Because of the much higher levels of TXB^
present in serum the RIA can be performed on a very much smaller 
sample than with plasma.
4.7 (c) Results
Figure 4.4 shows the levels of TXB^ obtained from normal
individuals. The horizontal axis gives the bleeding time in
minutes and the vertical axis the TXB2  levels in ng/ml.
The mean level of TXB^ in the first two minutes was 255.5 4^
99.2 ng/ml (SD) with a range of 106-400ng/ml which is similar to
our levels for serum TXB^.
We calculated the correlation between the mean level of TXB^ 
for the first two minutes and the bleeding time and found a
significant correlation (r = 0.79). This is shown in Figure 4.5.
4.7 (d) Discussion
In theory one would expect that the more TXA^ generated the 
shorter the bleeding time, giving a negative correlation. At 
first sight it therefore seemed surprising to obtain a positive 
correlation. However on re-examination of the data it was seen 
that in many cases volunteers with fairly long bleeding times had 
high levels of TXB^ at each time interval whereas one volunteer 
from whom we were able to obtain only one sample at two minutes 
had undetectable levels of TXB^ as is shown in table 4.7.
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FIGURE 4.5: CORRELATION BETWEEN BLEEDING TIME AND
THROMBOXANE GENERATION IN BLEEDING TIME 
BLOOD
Volunteer A Volunteer B
Time TXB? Time TXB?
(min) (ng/ml) (min) (nÿml)
1 400 1 no sample
2 400 2 4
3 400
4 400
5 400
6 400
7 400
8 400
Table 4.7 - Bleeding Time serum TXB? levels in two normal 
volunteers
We thought therefore that the levels we were measuring may be 
simply a reflection of the platelet count in the sample.
If the bleeding time is short, platelets will adhere to the 
surface of the incised vessel and therefore there will be fewer 
platelets in the sample to generate TXA^ during the incubation 
period. In order to try to prove this we repeated the bleeding 
time TXA^ generation test on six new volunteers. This time we 
sanpled TXB^ serum levels as before but took blood from one of 
the incisions into a lOjal capillary to perform a whole blood 
platelet count using an Ultra Flow 100 whole blood aggregometer. 
The results of this experiment are shown in Figure 4.6.
This experiment did show a significant positive correlation 
(0.52). However many of the values for serum TXB^ were greater 
than the maximum limit of detection of the assay which is 
400ng/ml. Since such a small initial volume of serum is obtained 
using this method it was therefore impossible to repeat these 
samples at a higher dilution which may have given a closer 
correlation.
We feel that this new technique is a useful method to measure the 
amount of thromboxane produced by platelets in response to 
vascular injury. This will be further discussed in Chapter 9.
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Platelet count 
(x 10^/litre)
300
200
100
100 200 300 400 TXB
(ng/ml)
Figure 4.6 : Serum TXB^ in bleeding time blood 
(average of first two minutes)
CHAPTER 5 - CLINICAL SIGNIFICANCE OF PROSTACYCLIN/THROMBOXANE
BALANCE. EFFECTS OF S0I4E VARIABLES ON THIS BALANCE
5.1 Introduction
Since it was discovered that prostacyclin (PGl^) and
thromboxane A^ (TXA^), both products of arachidonic acid
metabolism, have directly opposing biological actions there has 
been much interest in the role each plays in the clinical field. 
TXA^ is a powerful vasoconstictor and induces platelet 
aggregation while PGI2  is a potent vasodilator and inhibitor of 
platelet aggregation. It would thus seem logical to suppose that 
manipulation of the balance between the two substances could
offer a possible approach to the treatment and prevention of 
various diseases. To date several diseases have been shown to be 
associated with an imbalance in the PGI2 /TXA2  system. As far 
back as 1977 Legarde showed that platelets from patients with 
arterial thrombosis, deep vein thrombosis or recurrent venous 
thrombosis produce more prostaglandin endoperoxides and TXA2  
than normals and that their platelets also have a shorter life 
span than normals. Shimamoto and colleagues (Shimamoto 1978)
have shown that platelets from rabbits in which atherosclerosis 
has been induced by dietary manipulation produce more TXA2  and 
are more sensitive to aggregating agents than platelets from 
control rabbits. The same has also been claimed in patients who 
have survived myocardial infarction (Szczeklik 1978). More 
recently (Yui 1984) it has been shown that there is a significant 
reduction in serum PGI2  stimulating factor in patients with 
acute myocardial infarction compared to patients with angina 
pectoris or normals. They also found that this activity was much 
lower immediately after infarction than 80 _+ 17 hours later.
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Hirsh (1981) measured TXB levels in coronary sinus blood from 
patients with unstable angina. They found local TXA^ release 
to be associated with recent attacks of angina but were unable to 
determine whether this was cause or effect. Harrison (1978) 
showed that diabetic rats had increased release of TXA^ from 
their platelets and reduced PGIg production from their blood 
vessels. This was shown to be reversible after long term 
treatment with insulin. Johnson (1979) has also shown decreased 
PGI^ production by blood vessels from diabetic patients. In 
diabetics complicated by proliferative retinopathy circulating 
levels of 6 -keto-PGFloC when measured by GCMS have been shown to 
be reduced (Dollery 1979). However Davis et al (1981) failed to 
show this decrease in circulating levels of 6 -keto-PGFloC when 
measured by RIA, though they were able to confirm the decreased 
PGI^ production from blood vessels. Discrepancies in results 
of circulating levels of 6 -keto-PGFloC are not uncommon and are 
probably due to differences in methodology as discussed in 
chapter 3. Takahashi (1985) have shown that the activity of 
thromboxane synthesis as measured by the conversion by platelets 
of exogenously added ^^C-arachidonic acid into ^' C^-TXB^  was 
significantly higher in diabetic patients than in controls. 
Although there was no significant difference there was a trend 
towards increased synthesising activity as diabetic retinopathy 
developed. This activity was shown to decrease significantly on 
treatment with insulin whereas patients treated by diet or by 
sulphonylureas maintained their elevated thromboxane synthesising 
activity. Sensaki (1985) examined the ability of plasma from 
diabetic patients to stimulate PGI^ production from "exhausted" 
rat aortic tissue.
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Diabetics showed a significant reduction in this PGI^ 
stimulating factor compared to controls. Patients with diabetic 
retinopathy also showed a significant decrease when compared to 
patients without this complication. The abnormality appeared to 
be reversible and related to the degree of diabetic control. 
Urinary levels of 6 -keto-PGFloC have been shown to be greatly 
increased in patients with Bartter's syndrome (Gulner 1979). 
Urinary excretion of 6 -keto-PGFl od has been shown to be decreased 
in patients with essential hypertension (Grose 1980) whereas 
enhanced production has been reported in blood vessels
from spontaneously hypertensive rats (Pace-Asciak, 1978). 
Urinary levels could however reflect reduced PGI^ production 
from the kidney itself rather than from the whole body. A 
reduction in plasma levels of 6 -keto-PGFl od has however been 
shown in patients with essential hypertension compared to 
controls (Uehara 1983). Ihey found a significant negative 
correlation between mean blood pressure and plasma levels of 
6 -keto-PGFl oC . It has been suggested that increased TXA2  
production due to the effects of bilirubin may contribute to the 
haemostatic disturbancies in neonatal hyperbilirubinemia (Kaapa
1985). Newborns suffering from idiopathic respiratory distress 
syndrome have been found to have significantly elevated levels of 
plasma 6 -keto-PGFl ©C (Kaajpa 1982, Hutchison 1985). Defreyn 
(1981) has shown a link between a familiar bleeding tendency and 
a partial deficiency of thromboxane synthetase. Prostacyclin and 
thromboxane have also been reported to be associated with various 
pathological conditions of pregnancy but this will be discussed 
separately in chapter 8 .
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From this selection of the hundreds of papers written on PGI^ 
and TXA in various disease states it is apparent that there is 
much interest in the subject. It would seem possible that in 
diseases where there is a tendency for the development of 
thrombosis, PGI^ production is decreased or TXA^ production 
increased or both. The opposite may be true in diseases 
associated with a bleeding tendency.
5.2 Inhibition of Cyclo-oxygenase by Acetylsalicylic Acid
5.2 (a) Introduction
One of the most important discoveries in the development of our 
knowledge of prostaglandins was when Vane and colleagues (Vane 
1971) demonstrated that PGIg synthesis could be inhibited by 
acetylsalicylic acid (aspirin (ASA)). This gave a method by 
which it was theoretically possible to manipulate the 
cyclo-oxygenase pathway. However ASA binds covalently to the 
active site of cyclo-oxygenase and therefore inhibits TXA2  
production as well as PGI2  (Steiner 1970). Since platelets are 
unable to synthesise new proteins the enzyme action is inhibited 
for the entire lifespan of the platelet. Recovery of thromboxane 
generation only takes place gradually as platelets are renewed 
and complete recovery takes approximately 10 days. Inhibition of 
vascular cyclo-oxygenase may however persist for a much shorter 
period because of the ability of the vasculature to produce new 
enzyme. There has been much interest shown in the possible 
theraputic value of prolonged treatment with low dose ASA as an 
antithrombotic agent. The inhibition of platelet thromboxane 
generation while still sparing cyclo-oxygenase in the systemic 
peripheral vasculature therefore represents the pharmacological
goal for solving the so-called "aspirin dilemma".
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O'Grady and Moncada (1978) showed that in healthy volunteers aged 
20-34 years, ingestion of a single dose of aspirin of 0.3gm 
significantly prolonged the bleeding time, but a dose of 3 .9 gm 
had no significant effect on the bleeding time. The same group 
(Amezuca 1979) showed that following a single high dose of 3.9gm 
of aspirin given orally the bleeding time was unchanged 2  hours 
later, although there was marked inhibition of platelet function 
and TXA^ release was demonstrable. Twenty four and seventy two 
hours afterwards the bleeding time was significantly increased 
returning to normal one week after the administration of 
aspirin. This suggests that shortly after a high dose of aspirin 
the production of both TXA^ and PGI2  were blocked. As the 
endothelial cyclo-oxygenase recovery was quicker than the release 
of new platelets, the ratio of PGI^ to TXA^ was changed in 
favour of PGI2  at 24 and 72 hours after treatment, thus 
explaining the increased bleeding time and its slow recovery of 
up to one week.
Patrono et al (1980) found that with low doses of aspirin : 0.33 
- 0.40 mg/kg body weight there was a remarkable degree of
individual susceptibility to the inhibitory effect of the drug on 
serum TXB2  levels. This is consistent with the wide 
variability of the inhibitory effect in vitro (Patrono, 1978). 
Patrono (1980) also found that a dose dependent reduction of the 
inhibitory effect of aspirin could only be seen below a threshold 
dose of 2 mg/kg bodyweight. Thus it would appear that in a 
normal healthy subject a single oral dose of 2  mg/kg gives a 
maximal effect on TXA2  generation by platelets. Burch et al 
(1978) however found that a maximal effect of 95% was obtained 
only after a single dose of 650 mg.
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It has been suggested that perhaps some of the dilemma is caused 
by wide inter-individual variability of aspirin pharmacokinetics 
(Cerlitti 1985). It has also been suggested that an enteric 
coated preparation of aspirin may deliver little or no aspirin to 
the peripheral circulation (Ali 1980, Brantmark 1982). The 
inhibitory effects on platelet cyclo-oxygenase would be the same 
but vascular PGI^ synthesis would be spared in the absence of 
detectable peripheral aspirin levels. However Cerletti et al 
(1985) found that aspirin levels were undetectable in plasma from 
three out of the 6  subjects receiving the compressed form of 
aspirin (320mg) and in 2 out of 6  receiving the enteric coated 
preparation (800mg) two hours after conpressed aspirin and four 
hours after the enteric coated preparation supporting the 
suggestion of inter-individual viarability. However because of 
the potential for erratic absorption of aspirin especially in 
enteric coating, sampling may require to be more prolonged after 
ingestion. Rao et al (1985) showed that by 6  hours post 
ingestion plasma samples from all patients taking 650 mg of 
enteric coated aspirin showed significant levels of aspirin in 
their plasma and the only difference between the enteric coated 
and compressed preparations was in the initial delay in the 
inhibitory effect due to the slow release from the enteric coated 
formulations. It may be however that if there is in fact wide 
inter-individual differences in aspirin pharmacokinetics, if 
aspirin were to be successfully used as a long term 
anti-thrombotic drug, each individual would require to be 
assessed to find the optimum personal dose which would inhibit 
platelet thromboxane generation while sparing vascular 
cyclo-oxygenase.
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Recently Heavey (1985) showed that when PGI^ production was 
stimulated in normal volunteers by an intravenous infusion of 
bradykinin an oral dose of 600 mg aspirin caused rapid and 
substantial inhibition of PGI^ production. Recovery however 
occurred within six hours showing that even with this dose of 
aspirin PGI^ synthesis would be spared most of the time if 
dosing once daily.
5.2 (b) Importance of the acetyl group in inhibition of
cyclo-oxygenase
It is thought that it is the acetyl group in ASA that binds to 
cyclo-oxygenase thus inhibiting its action. The most well known 
use of ASA is as an anti-inflammatory drug. In some situations 
it is important that there is no anti platelet action when 
anti-inflammatory drugs are required for example in diseases 
associated with a bleeding tendency. In order to try to 
demonostrate whether or not the acetyl group is important in 
inhibition of cyclo-oxygenase we carried out a study to compare 
the effects of ASA with choline magnesium trisalicylate (CMT) on 
the cyclo-oxygenase pathway. CMT lacks the acetyl group of 
aspirin and the chemical structure of each drug is shown in 
figure 5,1.
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COOH
C -C H
COOH
Salicylic acid Acetyl Group
ACETYLSALICYLIC ACID (Aspirin)
OHOH
000COO
Mg
OH
COO
Choline
CHOLINE MAGNESIUM TRISALICYLATE (CMT) 
Figure 5.1 : Structure of aspirin and CMT
5.2 (b) (i) Design of study
In our study ten healthy volunteers 6  males and 4 females aged 20 
- 24 were given either 525mg aspirin which contains SOOmg of
salicylate or an equivalent salicylate dose of CMT. Each 
volunteer received both drugs with an interval of at least two 
weeks between. Samples were taken immediately prior to and 24 
hours post ingestion of the drug. Ihe parameters we examined
were plasma and serum TXB^ levels; TXA^ generation in 
response to aggregation with 4ug/ml collagen; serum TXB2  in 
bleeding time blood; bleeding times and plasma levels of PGI2  
metabolites. The methodology for all these tests is described in 
chapters 3 and 4.
5.2 (b) (ii) Results
The following figures shows results for the various parameters 
measured.
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5.2 (b) (ill) Conclusions
Our results show significant inhibition of thromboxane synthesis 
twenty-four hours after ingestion of a single oral dose of 625mg 
aspirin. After an equivalent salicylate dose of CMT however 
there was no significant differences in any of the parameters 
measured except serum levels of TXB^ which were significantly 
decreased at the 5% level twenty four hours after CMT. Plasma 
levels of PGI2  metabolites were not significantly different 
after either aspirin or CMT. However since normal levels of 
PG% 2  metabolites are very close to or below the limits of 
sensitivity of our assay it is not possible to use this 
measurement to detect decreases in PGI2  production. Since CMC 
lacks the acetyl group of aspirin it is therefore unable to block 
the arachidonic acid pathway by acétylation of the enzyme 
cyclo-oxygenase. If analgesics are required by patients in whom 
an anti platelet effect is undesirable, for example those with a 
bleeding disorder, a salicylate such as CMT which lacks the 
acetyl group would seem to be preferable.
5.3 Inhibition of cyclo-oxygenase by indomethacin
5.3 (a) Introduction
Indomethacin is an anti-inflammatory drug which is also 
known to inhibit prostaglandin and thromboxane synthesis. 
The structure of indomethacin is shown in figure 5.8.
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MeO 
i^ ^ C O H
Figure 5.8 - Structure of indomethacin
5.3 (b) Methods
In order to demonstrate inhibition by indomethacin using our 
methodology we allowed the blood to clot in the presence of 
indomethacin. A series of glass tubes were prepared containing 
either indomethacin at varying concentrations or saline. Blood 
was taken from a normal volunteer and 1 ml aliquots were 
immediately put into the previously prepared glass tubes, mixed 
and left to incubate for one hour at 37°C. Ihe tubes were then 
centrifuged at 2500 and 4°C for 15 minutes. Ihe serum was 
separated and aliquots stored at -70°C for RIA for PGI2  
metabolites and TXB^ as described in Chapters 3 and 4 
respectively. Ihe experiment was repeated eight times at each 
concentration.
5.3 (c) Results
Figures 5.9 and 5.10 show the levels of serum TXB^ and plasma 
PGI2 metabolites respectively at each concentration of 
indomethacin (mean + SD).
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5.4 Prostaglandins and Essential Fatty Acids
In the 1920's it was discovered that when rats were fed on a 
purified, fat-free diet a deficiency syndrome developed with 
completely different symptoms from those of vitamin E 
deficiency. By feeding the rats different fats it was shown that 
the substance in the fats which prevented the deficiency syndrome 
/ was in the fatty acid fraction. Linoleic acid, ^  -linoleic acid
and arachidonic acid gave similar results and the generic term 
essential fatty acid (EFAS) was given (Burr et al 1930).
At the same time as knowledge of the EFA's grew, knowledge of the 
prostaglandins increased and gas-liquid chromatography enabled 
the structure of the primary prostaglandins to be elucidated. 
Ihe presence of the double bonds in the prostaglandins led 
Bergstrcm et al 1964 and Van Dorp et al (1964) to suspect that 
the prostaglandins had their origin in the EFA's and both groups 
provided evidence that this was in fact true. This work led to 
the elucidation of the arachidonic acid cascade (Hamberg et al 
1974).
Originally it was thought that because the amounts of 
prostaglandins synthesised were so small and the amounts of the 
EFA precursors available in cells were comparatively large there 
could be no relationship between the EFA's and the regulation of 
PG biosynthesis. However studies on both humans and rats 
(Epstein 1981, Hornstra et al 1975) have provided evidence that 
dietary linoleic acid can augment prostaglandin production. When 
rats are given labelled arachidonic acid the label is found in 
the cell membrane phospholipids and in the prostaglandins 
relatively quickly suggesting the source of the PCs to be in the 
cell membrane.
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However this conflicts with evidence from studies done on rabbits 
(Hassam et al 1979) where rabbits fed on EFA deficient diets did 
not show any significant change in AA levels in membrane 
phosphoglycerides over a four month period. The rabbits appeared 
to conserve the AA and lose the docosahexaenoic acid. However 
the synthesis of PGE^, E^ and F^ dropped suggesting that 
there was a relationship between adipose stores of the precursor 
as opposed to cell membrane components. It has therefore been 
suggested that there are two sources of PG precursor : endogenous 
synthesis derived from a metabolic pool and stimulated synthesis 
derived from the cell membrane pool. The synthesis of PGs 
relates back ultimately to a dietary source of EFA but it would 
seem possible that there could be two levels at which the PG-EFA 
link operates: one in which the metabolism of dietary linoleic 
acid results in a PG precursor immediately available for PG 
synthesis the other using membrane AA released by a lipase as a 
direct percursor for PG synthesis. Whether these two sources 
lead to production of the same PG, if in fact the concept is 
correct, has still to be established. The membrane pool of PG 
precursor would be expected to be more stable and therefore 
susceptible only to long term changes in diet, whereas the 
metabolic pathway would be more likely to be directly influenced 
by dietary changes in EFA's and other fatty acids. If these 
theories are correct it gives the clinician another way of 
influencing physiological responses regulated by the 
prostaglandins and leukotreines using dietary manipulation.
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5.5 Dietary Studies
5.5 (a) Introduction
The enzyme systems for the metabolism of fatty acids in general 
are shared, which means that different fatty acids will compete 
with each other. It has been shown that saturated fats suppress 
essential fatty acid activity (Holman, 1977). It has been 
concluded from whole life studies that during the period in our 
evolution when man was a hunter-gatherer, food would have had a 
low fat content, but what fat there was would have been 
relatively rich in essential fatty acids (Crawford 1968 
The fat in the meat of wild animals or fish is mainly structural 
fat rich in phosphiglycerides. Plant food is also generally rich 
in essential fatty acids. In our modern domestic animals, which 
have been bred to produce meat, there is a higher proportion of 
saturated non essential fats. This is also true of much of our 
modern diet. The balance of fats in man's diet has therefore 
changed to the situation where non essential and saturated fatty 
acids dominate. In Western countries approximately 40% of the 
dietary energy comes from fat and about 4% of this is derived 
from essential fatty acids. It would thus seem likely that the 
essential fatty acids have significant competition with the 
saturated fats for the enzyme systems necessary for their 
metabolism. It may be that the high incidence of atherosclerosis 
and thrombosis in Western society is due to the high levels of 
saturated fat in our diet which lead to a relative deficiency of 
essential fatty acids. Thus the requirements for essential fatty 
acids in a Western diet could be higher than expected because of 
this competition with the non-essential fats.
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It is now generally accepted that the type and amount of dietary 
lipids may alter the thrombotic tendency of the blood. (Lowe et 
al 1979, Johnston et al 1982) and over a long term with the 
development of atherosclerosis (Heyden et al 1975). 
Epidemiological studies (Renaud 1979, Kannel 1970) indicate that 
a diet rich in saturated fats has a distinct negative influence 
on coronary artery disease, whereas a polyunsaturated diet might 
have a protective effect (Horstra 1973). In several other 
conditions associated with thrombosis and arterial disease 
platelet behaviour is influenced by alterations in dietary lipids 
(Nordoy 1971) and it has been well documented that alimentary 
hyperlipidaemia alone may cause platelet activation (Lowe et al 
1979, Johnston 1982, O'Brien 1976). That this may be linked to 
clinical disease is suggested by work done both by Regan (1961) 
and Kuo (1955) who demonstrated decreased oxygen delivery to the 
myocardium after a fat meal and an increased frequency of angina 
attacks in fat fed patients with ischaemic heart disease. The 
mechanism by which a saturated fat diet produced this platelet 
activation may be related to an alteration in prostanoid 
production and in particular to an increase in production of 
thromboxane A2  (Hornstra 1982). Because of this we decided to 
look at the effects on prostacyclin and thromboxane production of 
a saturated fat meal in healthy male volunteers. If the effects 
of saturated fat on platelets are mediated through an increase in 
TXA^ it might be reasonable to suppose that selective 
inhibition of TXA_ might normalise platelet behaviour. UK 38, 
485 (Pfizer Ltd) is an imidazole derivative which has been shown 
to inhibit thromboxane synthetase. Inhibition may have the added 
benefit of augmenting PGI. production (Parry 1983) which should
further protect against thrombosis.
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We therefore repeated the fat feeding experiment on the same 
subjects one month later after pretreatment with a thromboxane 
synthetase inhibitor.
5.5 (b) Subjects and Methods
Ethical permission was obtained. 10 healthy male volunteers of 
average age 28 + 7.1 years (SD) were enrolled in the study after 
giving informed consent. The protocol was similar to that used 
/previously (Lowe 1979, Johnston 1982). The subjects fasted for 
1 2  hours overnight after which baseline blood sanples were 
taken. 150ml of double cream were then ingested (fatty acid 
content see Table 5.1).
Further blood sanples were taken by separate venepuncture 2 and 4 
hours later and again after an overnight fast, 24 hours later. 
After a one month washout period the procedure was repeated but 
this time the subjects had received pretreatment with 1 0 0  mg of 
UK 38 485 twenty four, twelve and one hour before ingestion of 
the cream. TXB^ and PGI2 M were measured in plasma samples as 
described in chapters 3 and 4. Serum lipids were measured for us
in the routine biochemistry laboratory.
Table 5.1 shows the fatty acid composition of double cream.
Saturated 28.8g/100g cream
Monosaturated 15.4g/100g cream
Polyunsaturated 1.3g/100g cream
Table 5.1 - Fatty Acid Composition of Double Cream
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5.5 (c) Results
The results obtained are shown in Table 5.2. The first line of 
each pair is the control value and the second the results of pre 
treatment with a thromboxane synthetase inhibitor.
PRE 2  hrs 4 hrs 24 hrs
** **
Triglyeride 1 . 1  + 0 . 1 2 . 0  + 0 . 1 2.7 + 1.6 1 . 0  + 0 . 1 - UK
** **
mmol/ 1 1 . 1  + 0 . 1 2 . 0  + 0 . 1 3.1 + 1.9 1 . 0  + 0 . 1 + UK
Cholesterol 5.9 + 1.0 5.8 + 1.0 5.8 + 1.0 5.7 + 1.3 - UK
mmol/ 1 5.9 + 1.3 6.0 + 1.3 6.0 + 1.4 5.8 + 1.3 + UK
PGI2 M 11.9 + 3.2 12.1 + 4.3 12.6 + 4.6 13.4 + 4.1 - UK
pg/ml 14.3 + 3.9 14.4 + 4.7 12.4 + 4.2 16.6 + 13.9 + UK
TXB2 137 + 28 129 + 24 154 + 108 164 + 82 - UK
pg/ml 119 + 27 * 1 2 2  + 26 119 + 33 173 + 111 + UK
* p ^ 0 . 0 5  student t test
** p ^  0 . 0 0 1  paired t test
Table 5.2 - Plasma levels of triglyceride, cholesterol, PGI9
metabolites and TXB? with and without pretreatment 
with a thromboxane synthetase inhibitor
5.5 (d) Discussion
The only result to reach statistical significance was the 
baseline level of TXB^ after ingestion of UK 38 485. This is 
shown graphically in Figure 5.11. Baseline PGI2 M levels were 
higher after the UK 38 485 was given but this did not reach 
statistical significance. Our results therefore provide no 
evidence to suggest that the mechanism by which a saturated fat 
diet produces platelet activation is related to any alteration in 
the prostacyclin/thromboxane balance.
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5.6 Dietary Studies - Orally administered evening primrose oil 
to norml volunteers
5.6 (a) Introduction
'Efamol' capsules manufactured by Efamol Ltd were taken by ten 
normal healthy volunteers at a dose of 1 2  capsules per day for a 
ten week period. Ethical committee permission and informed 
consent had been obtained. Each capsule contained SOOmg evening 
primrose oil which supplies approximately 40mg gamma-1inoleic 
acid and 350mg linoleic acid in a shell composed of gelatin and 
glycerin. lOmg of natural Vitamin E is added to each capsule. 
Since prostaglandins of the 1-series can be obtained by anabolic 
desaturation and chain elongation from dihomo- ^ ^ 1  inoleic acid 
this might be expected to show a shift in metabolism away from 
the 2-series prostaglandins. Blood samples were taken prior to 
and at fortnightly intervals during ingestion of the Efamol 
capsules. Blood was handled and RIA of plasma PGI^ metabolites 
was performed as described in Chapter 3.7. In this study we also 
measured plasma PGE2  metabolites using a RIA kit supplied by 
Amersham Ltd, Amersham, Buckinghamshire.
5.6 (b) Results
The results of this study on PGI2  metabolites are shown 
graphically in Figure 5.12 and on PGE2  metabolites in Figure 
5.13.
5.6 (c) Discussion
Seven out of the ten individuals showed an increase in plasma 
levels of PGI^ metabolites at some point during the study 
although at no time did levels reach statistical significance.
— 81 —
S •
CmW
îs \ 00
• • t
•• •#*
rH
S
M
o o
ro
O
CN
0en o
^ y
> mH Oj
m w B W
iiEh
W < 
ot>
o ^A to
co m < Pu H rtC P, U
N
in
g
(m
PGE^M
200 N.S.D.
T
ee
100
ee
10862 4PRE
Time (weeks)
Figure 5,15: Plasma PGE^ metabolite levels in patients taking 
'Efamol' capsules
There was also no obvious sex difference: of the three who showed
no increase in levels of PGI^ metabolites two were male and one 
was female. PGE2  metabolite levels also show no significant 
difference. These results would therefore appear to show no 
evidence of a shift in prostaglandin synthesis away from the 
2-series prostaglandins. However since normal levels of PG% 2  
metabolites in plasma are at or near the lower limit of detection 
of the assay it is very unlikely to give statistically significant 
results where decreased PGI2  production would be expected. This 
will be discussed more fully in chapter 9 of this thesis. However 
PGE2  metabolite levels also showed no significant differences. 
In this study further investigation of the 1-series prostaglandins 
might have shown evidence of a shift from 2-series to 1-series
prostaglandins.
5.7 Cigarette smoking and PGl2 /TXA2 production
5.7 (a) Introduction
The incidence of ischemic heart disease is significantly increased 
in cigarette smokers (Fredrickson 1977) the risk being proportional 
to the number of cigarettes smoked. Although the exact
relationship between the two is not properly understood, enhanced 
platelet aggregability has been reported by several investigators 
(Glynn 1966, Levine 1973, Bierenbaum 1978). Some evidence has been 
published that this could be due to the direct effect of nicotine 
(Werle 1965, Saba 1975) but this is not confirmed by others
(Brinson 1974). However more recently the effect of cigarette 
smoking on platelet aggregation has been questioned (Seiss 1982, 
Laszlo 1983) and platelet hyperaggregability following acute 
cigarette smoking has been shown to be an immediate effect
disappearing within half an hour (Davis 1979, Hawkins 1972).
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cigarette smoking has also been shown to increase circulating 
platelet aggregates by some workers (Davis 1979) while others 
were unable to confirm this effect (Hillborn 1985). Smoking has
also been shown to increase platelet count (Seiss 1982). In the
earlier studies platelet count was not controlled and increasing 
platelet count could have been the reason for the supposed
increased platelet reactivity. A number of studies have reported 
an inhibitory effect of smoking on prostacyclin production 
(Nadler 1983 , Pittilo 1982 , Isotel 1982). It has also been 
shown that brief periods of smoking in non-smokers leads to 
increased TXA^ production but only a slight increase in
PGI2 . In contrast, similar periods of smoking in habitual 
smokers is not accompanied by increases in either TXA^ or 
PGI2  (Mehta 1982).
Nicotine has been shown to inhibit the release of PGIg in human 
and in laboratory animals' blood vessels (Alster 1981, Wennmalm 
1983) whereas other workers have been unable to show this 
(Hartiala 1982). Jeremy et al (1985) have shown that high 
concentrations of up to lg/1 of nicotine were unable to inhibit 
in vitro synthesis of PGI^ by human umbilical artery or by rat 
or rabbit aorta or rat lung. However they found that aqueous and 
ethanolic cigarette smoke extracts did inhibit PGI^ synthesis 
and release in these tissues. These extracts contained a maximum 
of 26mg/l of nicotine and therefore this excluded nicotine as the 
inhibitory conponent of the cigarette smoke extract. It would 
appear therefore that although cigarette smoking is well 
recognised as a major risk factor in the pathogenesis of vascular 
disease (Murphy 1966, Dawber 1959, Spain 1970), the evidence as 
to the mechanisms involved is still conflicting. Also evidence
of the involvement of PGI2 and TXA^ is unclear and 
inconclusive.
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5.7 (b) Design of Study
We measured plasma PCI. metabolite levels in six healthy male 
volunteers after acute smoking. Each subject smoked two 
cigarettes in succession and blood samples were taken at 0, 30, 
60 and 120 minutes thereafter as described in chapter 3.7(b). 
The volunteers were of average age 31.4 + 4.6 years (SD) and all 
were regular smokers.
5.7 (c) Results
The results for each individual are shown graphically in figure 
5.14.
5.7 (d) Discussion
Although the numbers are very small in this study four out of the 
six individuals studied showed an increase in plasma levels of 
PGI2  metabolites from the baseline level. Mehta (1982) showed 
a slight increase in plasma 6-keto-PGFloC levels after smoking in 
non-smokers although they were unable to detect this in habitual 
smokers. A study using larger numbers of volunteers would have 
been preferable and also a study of the effects of smoking on 
non-smokers. However we found it difficult to find larger 
numbers of habitual smokers to take part in the study. It also 
seemed unethical to persuade non-smokers to participate. However 
if this is in fact a true result it could be a defense mechanism 
to counteract the platelet hyperagregability found by some 
researchers (Glynn 1966, Levine 1973, Bierenbaum 1978).
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FIGURE 5.14 : Levels of plasma PGI metabolites after smoking
5.8 Conclusion
The studies presented in this chapter have shown that, using the 
methodology described in chapters 3 and 4, we can show inhibition 
of thromboxane production by aspirin and that the acétylation of 
the cyclo-oxygenase enzyme by the acetyl group of aspirin appears 
to be the mechanism by which this inhibition occurs. We have 
also shown inhibition of thromboxane and prostacyclin in whole 
blood incubated with indomethacin. The dietary studies on 
ingestion of double cream and also of 'Efamol ' capsules show no 
changes in the thromboxane/prostacyclin balance after dietary 
manipulation.
There is some indication that the balance of thromboxane 
prostacyclin may be altered in favour of prostacyclin after 
smoking in some subjects but a larger study would be necessary to 
show whether this is of clinical significance in somking related 
diseases and this is discussed in chapter 9.
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CHAPTER 6 - PROSTACYCLIN AND THROMBOXANE IN SOME 
VASCULAR DISEASES
6.1 Raynaud's Syndrome
6.1 (a) Introduction
Raynaud's phenomenon is the name given to a peripheral vascular 
disturbance consisting of spasmodic contraction of the digital 
arteries, which is precipitated by cold and emotion. Primary 
Raynaud's phenomenon is commonest in young women and is an 
exaggerated physiological response to cold. Secondary Raynaud's 
occurs in response to various factors one of which is associated 
with certain occupations in which the arms and hands are exposed 
to vibrating tools e.g. pneumatic drills, chain saws, polishing 
tools etc. Secondary Raynaud's may also occur in connective 
tissue disorders especially scleroderma. In the early 
uncomplicated stages there are no pathological changes, however 
thrombosis in the lumen may develop later leading to ischaemic 
changes in the skin of the fingers and in the nails, followed by 
superficial necrosis and finally gangrene (De Takatas 1962). 
Fingers are usually more affected than toes and the clinical 
presentation would be numbness, tingling, burning and then pain. 
Sensitivity to cold may be extreme and disabling. In varying 
degrees of severity Raynaud's phenomenon exists in 5-10% of the 
population (Blunt 1981). However in the vast majority of cases 
it requires only avoidance of cold and the wearing of gloves to 
relieve the synptions. Various methods of treating the severe 
cases of Raynaud's syndrome have been tried: intra-arterial
reserpine (Elbaor 1971) oral vasodilators (Leyroy 1971)
f .
! sÿathectomy (De Takatas 1962), fibrinolytic enhancement (Jarrett 
1981) and plasma exchange (Zahavi 1980) have been used with 
varying effect.
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6.1 (b) Prostacyclin and Thromboxane in Raynaud*s syndrome
Recently treatment with PGIg has been shown to be of benefit to 
patients suffering from Raynaud's phenomenon (Belch 1981) as has 
treatment with prostaglandin (Clifford 1980). Intravenous 
infusions of these prostaglandins have been shown to increase 
blood flow for up to six weeks after the infusion. The clinical 
improvement observed after infusion would suggest either 
inadequate production of the vasodilatory prostaglandins or 
resistance to normal or even increased production. Platelets 
from patients with Raynaud's phenomenon have been found to be 
less sensitive to the ant i-agg r egatory effects of PGE^  ^ and 
PGIg when cooled to 27°C (Mikhailidis 1981). It has also 
been shown that lynphocytes (Inoshita 1981) and endothelial cells 
(Whicker 1980) from patients with systemic sclerosis are more 
resistant than normal to the effects of the E-series 
prostaglandins. In systemic sclerosis collagen deposition in 
vessels may contribute to the development of Raynaud's 
phenomenon. Fiocco (1982) and Horrobin (1983) have reported 
increased prostaglandin levels in patients with systemic 
sclerosis. These studies provide evidence of cellular resistance 
to rather than inadequate production of the vasodilatory 
prostaglandins.
6.1 (c) Plasma levels of PGI^ metabolites in patients with
R a y n a u d 's  syndrom e
6.1 (c) (i) Patients and Methods
Using the methodology described in chapter 3 we measured plasma 
levels of PGIg metabolites in fifteen patients with Raynaud's 
syndrome alone and in fifteen patients with systemic sclerosis
a n d  R a y n a u d 's  sy n d ro m e .
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None of the patients was taking any drug known to alter 
prostaglandin production and none were on the contraceptive 
pill. Fifteen age and sex matched controls were also studied. 
Patients were left to sit in a warm room for at least half an 
hour prior to blood sampling to ensure that no blood sample was 
taken during a Raynaud's attack. The samples were coded so that 
the assays were performed blind.
6.1 (c) (ii) Results
The levels of plasma PGI^ metabolites in each group are shown 
in table 6.1
Pr imary
Raynaud's Raynaud's + 
phenomenon system sclerosis Controls
PGIo metabolites 11 + 2 51 + 5 * 16 + 2
(pg/ml) “  “
* p < 0.01
Table 6.1 - Plasma PGI^ metabolite levels in patients with 
Raynaud's phenomenon and systemic sclerosis, 
Raynaud's phenomenon and controls (+ SD)
6.1 (d) Raynaud's phenomenon associated with vibratory injury
6.1 (d) (i) Introduction
In some patients with Raynaud's phenomenon the disease is 
associated with certain occupations in which the arms and hands 
are exposed to vibrations from machinery used at work such as 
pneumatic drills or polishing tools. The term secondary 
Raynaud's phenomenon is used to describe this type of clinical 
syndrome.
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PGl^ metabolites and plasma TXB^ levels were measured in
fifteen patients with this type of secondary Raynaud's
phenomenon. We compared them to age and sex matched controls and 
also to fifteen patients with primary Raynaud's phenomenon. The
methodology used is described in chapters 3 and 4.
6.1 (d) (ii) Results
I Plasma levels of PGl^ metabolites in fifteen patients with
Raynaud's syndrome caused by vibratory injury are shown in table
6.2 compared to patients with primary Raynaud's phenomenon and 
controls.
Secondary Primary
Raynauds Raynauds Controls
*
PGI2  metabolites 24.9 + 16.2 11 + 2 16 + 2
(pg/ml)
**
TXB2  (pg/ml) 131.8+32.9 104.1+38.2 95.9+25.7
* significantly different from controls p<*i0.05 and from 
secondary Raynaud's p*^ 0.01
** significantly different from primary Raynaud's and controls 
p<0.005
Table 6.2 - Plasma levels of PGI? metabolites in patients
w i t h  s e c o n d a ry  R a y n a u d 's  a s s o c ia te d  w i t h  v i b r a t o r y  
i n j u r y  co m p ared  t o  p a t i e n t s  w i t h  p r im a r y  R a y n a u d 's  
an d  c o n t r o ls
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6.1 (e) Discussion
This study has shown increase levels of plasma PGIg metabolites 
in patients with systemic sclerosis and Raynaud's phenomenon and 
also in patients with secondary Raynaud's phenomenon associated 
with vibratory injury. Since it has previously been shown that 
intravenous infusions of PGI^ are beneficial in Raynaud's 
syndrome (Belch 1981, Dowd 1982) this result was unexpected. 
However this increase PGI^ production may be a compensatory 
mechanism. Vascular damage is known to occur in systemic 
sclerosis. In the early stages this is suggested by an increase 
in factor VIII released from the endothelium (Kahaleh 1981) and 
later microscopic changes can be demonstrated (Kahaleh 1979). 
Since the endothelium produces PGI2  in response to noxious, 
chemical or mechanical stimuli (Ritter 1983) repeated vasospastic 
attacks could lead to a chronic increase in PGI^ production. 
Since the blood vessels would then be chronically subjected to 
these high levels of PGI2  the muscle cells may have become 
desensitised to the action of PGI2 . Another possibility is 
that the cells are resistant to the effects of PGI2 . PGI2  
increases cyclic AMP and it is thought that this acts as a 
negative feedback to PGI2  production (Horrobin 1980). If this 
increase in cyclic AMP fails to occur due to cellular resistance 
an excess of PGI2  will be produced. This cellular "resistance" 
could be an inherited defect or it may be due to blockage of cell 
membrane receptor sites by immune complexes (Moretta 1978). 
Pharmacological doses of PGLg have been shown to normalise the 
cyclic AMP levels in systemic sclerosis lymp^ytes and this 
"resistance" may therefore be overcome by infusions of PGI2 *
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Plasma TXB^ levels are significantly increased in patients with 
secondary Raynaud's phenomenon (p 0.005) when compared to 
either controls or to patients with primary Raynaud's 
phenomenon. This indicates increased platelet activation in 
these patients which could be a contributory factor to the degree 
of severity of the disease with platelets causing blockage of 
small vessels. The increased levels of plasma PGI^ metabolites 
may be a conpensatory mechanism in an attempt to counteract the 
high levels of TXB^.
6.2 Vascular disorders in diabetics
6.2 (a) Introduction
Vascular disease is the major long term problem in diabetes. In 
diabetics over the age of fifty years arterial diseases are the 
commonest cause of death, the mortality rate being much higher 
than would be expected in a non-diabetic population of this age 
(Garcia 1969). Diabetic retinopathy is the most important 
systemic disease causing blindness in those aged between 30 and 
64 years of age. Atherosclerosis occurs commonly and extensively 
in diabetics being more widespread and occurring earlier than in 
non diabetics (Garcia 1974). Thus diabetics are prone to 
intermittent claudication and grangrene and myocardial infarction 
prematurely. Diabetics are also more likely to develop 
thrombosis than non-diabetics (Timperley 1970).
6.2 (b) Involvement of prostacyclin and thromboxane in diabetes 
Depressed vascular PGIg production in vitro was first shown in 
diabetic rats treated with streptozocin (Harrison 1978).
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In diabetic patients depressed PGl^ production was found from 
arterial segments removed at operation (Johnson 1979) and from 
samples obtained at elective vein biopsy (Silberbauer 1979). 
Treatment with insulin has been shown to restore vascular PGI2  
production to normal (Harrison 1980). Uncontrolled diabetes in 
man is linked with the development of both large vessel (Garcia 
1974) and small vessel (Jarrett 1976) disease and decreased 
vascular PGI2  production could be associated with this. There 
is conflicting evidence as to whether diabetics with 
microangiopathy have lower PGI2  levels than normal non-diabetic 
controls or diabetics without microangiopathy (Dollery 1979, 
Mitchell 1978, Davis 1981).
Decreased PGI2  production has been shown from aortic tissue 
from chronically diabetic pregnant rats which appears to be 
related to the duration of the disease (El Tahir 1982). 
Betteridge (1982) showed that platelets from 30% of diabetic 
patients showed a marked decreased in their sensitivity to the 
antiaggregation action of PGI2 . Those diabetics with vascular 
disease had significantly decreased platelet sensitivity to 
PGI2 . Those without vascular disease did not have a 
significant decrease in platelet sensitivity.
More recently (Takahashi 1985) showed a trend towards increased 
thromboxane synthetase activity as diabetic retinopathy develops 
through these differences did not reach significance. However in 
all diabetics studied the thromboxane synthetase activity was 
significantly higher than in age and sex matched controls. Other 
studies have shown increased thromboxane production in diabetics 
using a variety of exogenous aggregating agents (Gensini 1979, 
Halushka 1981).
- 92 -
However Carter (1986) has shown that the synthesis of TXB^ by 
clotted whole blood from diabetics was significantly lower than 
from controls with no difference between those taking oral 
hypoglycaemic drugs than that in those receiving insulin. They 
also showed that TXB^ synthesis is influenced by the degree of 
diabetic control.
It has been shown that plasma from diabetic patients showed a 
decreased ability to stimulate PGI2  release from exhausted rat 
aortic tissue compared to controls and that patients with 
diabetic retinopathy showed decreased stimulatory activity. When 
compared to those without this complication (Sensaki 1985).
6.2 (c) Plasma levels of PGI2  metabolites and TXB2  in diabetics
6.2 (c) (i) Patients and Methods
We measured plasma levels of PGI2  metabolites in 27 diabetics 
with varying degrees of vascular involvement. There were 17 
males and 10 females in the group, the ages ranging from 21 - 75 
years with an average age of 51.7 + 14.4 years (S.D.) We 
compared these patients with 27 age and sex matched controls.
None of the patients or controls were taking any drugs known to 
alter prostaglandin production. The methodology used for sanple 
preparation and assays was as described in Chapters 3 and 4.
6.2 (c) (ii) Results
The plasma levels of PGI2  metabolite and TXB2  showed that 
diabetic patients had higher levels of PGI2  metabolites and 
lower levels of TXB2  than controls. The results are shown in 
table 6.3.
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Diabetics Controls
PGI2 M (pg/ml) 18.6 + 1 0 . 0  * 9 . 9  + 3 . 9
TXB2  (pg/ml) 74 + 24.6 * 102.7 + 21.3
Significantly different from controls p ^  0.001
Table 6.3 - Plasma levels of PGI9  metabolites and TXB9
in diabetic patients and controls (mean + SD)
We examined the results further by dividing the diabetic patients 
into those with juvenile onset diabetes mellitus on insulin 
treatment (Type I) and those with non-insulin dependent diabetes 
treated with diet and/or oral hypoglycaemic drugs (Type II). We 
found that Type II diabetics had significantly higher levels of 
PGIg metabolites than those with Type I diabetes (p 0.005) 
but there was no significant difference in plasma TXB^ levels. 
These results are shown in table 6.4.
Type I (i.d.) Type II (n.i.d.)
PGI2 M 15.2+6.1* 26+12.7
TXBo 6 8 . 1 + 2 1 . 5  81.7+27.3
(pg/ml)
(Means + S.D.)
* significantly different from Type II p <1 0.005
Table 6.4 - Plasma PGI9  metabolite and TXB9  levels in Type I 
and Type II diabetics
When we examined patients of both types who had vascular 
conplications and compared them to those diabetics with no 
vascular complications, we found no significant differences in 
plasma levels of PGI2  metabolites or TXB2 .
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6.2 (d) Discussion
The increased levels of PGI^ metabolites we have found in 
diabetic patients compared to controls would seem to be in 
disagreement with the findings of depressed PGIg production 
from arterial (Johnson 1979) and venous (Silberbauer 1979) human 
tissue, and from rat aortic tissue (El Tahir 1982). However 
this, together with our finding of increased plasma levels of
PGI2  metabolites in patients with secondary Raynaud's syndrome 
and patients with Raynaud's phenomenon and systemic sclerosis 
(6 .2 ) indicates that higher levels of PGIg metabolites may be
associated with vascular diseases.
The finding of decreased platelet sensitivity to PGIg in some 
diabetic patients (Betteridge 1982) would perhaps indicate that 
the platelets had been subjected to chronically high levels and 
thus become desensitised. The decreased plasma levels of TXB2  
which we have found in diabetic patients when compared to
controls is supported by the recent finding of decreased serum 
TXB2  levels in diabetics (Carter 1986). Most other researchers 
have however shown increased thromboxane production and further 
study of thromboxane generation is required in an attempt to
clarify this.
6.3 Prostacyclin and Thromboxane in Cardiovascular Disease
6.3 (a) Introduction
The potent and contrasting effects of PGI2  and TXA^ on 
vascular tone and platelet function have led researchers to 
suppose that the balance between the two may play an important 
role in human cardiovascular disease.
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Some of the first work published on plasma TXB^ levels from 
patients with variant angina due to coronary artery spasm found 
detectable levels of TXB^ in these patients whereas levels were 
undetectable in healthy volunteers (Lewy 1979 a). They were also 
able to show beneficial clinical effects in these patients with 
aspirin therapy concluding that thromboxane generation appears to 
be a pathogenic factor in Prinzmetal's angina (Lewy 1979 b). In 
1981 Robertson and colleagues (Robertson 1981) reported that 
peripheral venous levels of TXB^ at baseline and during an 
episode of chest pain were almost undetectable, whereas levels 
were increased several minutes after the vasopastic event. In 7 
out of 8  episodes of coronary vasospasm, coronary sinus levels of 
TXB2  increased to detectable levels within 2  minutes of the end 
of the attack. It would seem reasonable to suppose that since 
coronary arterial flow is diminished because of vessel 
constriction during an attack, a mediator such as TXA2  may not 
appear in the coronary venous effluent until the end of the 
vasospastic attack. Other researchers have concluded that since 
treatment with aspirin or indomethacin failed to influence either 
the frequency or the severity of attacks of angina, thromboxane 
does not play a role in the disease.
However, as discussed in chapter 5.2, aspirin and indomethacin 
block the cyclo-oxygenase pathway unselectively and it may be 
possible that there is an optimum dose for each patient which 
blocks the thromboxane pathway while allowing recovery of 
endothelial cell production of PGIg. It may be that the dosage 
given to these patients was blocking production of PGI2  as well 
as thromboxane.
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It has been tentatively suggested that PGI may be involved in 
the etiology of variant angina. However this is based only on 
clinically significant benefit being observed in one out of nine 
patients treated with an infusion of PGIg (Chierchia 1982).
Tada (1981) reported increased TXB^ production during rapid 
cardiac pacing in patients with chronic stable angina. However 
Martin (1983) found no intracoronary release of TXB^ during 
rapid cardiac pacing in patients with coronary artery disease, 
but did show TXB^ release immediately after pacing in those 
patients with evidence of myocardial lactate production. Hirsh 
(1981) studied 52 patients with chronic stable angina subjected 
to rapid cardiac pacing and observed no increase in coronary 
sinus or transcardiac levels of TXB^ despite the production of 
myocardial ischemia in many of these patients. It has been 
suggested that in addition to the influence of sampling 
techniques and assay methodology on results as discussed in 
chapter 4 another reason for conflicting results may be the 
diagnostic criteria used by various investigators for patient 
classification.
6.3 (b) Plasma levels of PGI^ metabolites and TXB^ in patients
with coronary artery disease
6.3 (b) (i) Patients and Methods
We measured plasma levels of PGI^ metabolites and TXB^ in 6  
patients with coronary artery disease who had had a previous 
myocardial infarction and compared them to six patients vriio had 
coronary artery disease without myocardial infarction and six 
normal age and sex matched controls. Coronary heart disease was 
defined as >50% occlusion of a major coronary vessel shown by 
coronary angiography.
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The methodology used for sample preparation and assays was as 
described in chapters 3 and 4. None of the patients had taken 
any drugs known to alter prostaglandin production during the 
previous two weeks.
6.3 (b) (ii) Results
The results for all coronary artery disease patients compared to 
age and sex matched controls are shown in table 6 .5 .
CAD Patients Controls
PGI2 M 15.8+5.2 11.9+4.0
TXB2  127.1+39.2 103.8+ 36.6
Table 6.5 - Plasma PCI? metabolite and TXBp levels (pg/ml)
in patients with coronary artery disease compared to 
age and sex matched controls (means + SD)
The results for plasma PGI^ metabolites and TXB^ levels in 
patients with and without previous myocardial infarction are 
shown in table 6 .6 .
Myocardial CAD but no
Infarction myocardial infarction Controls
PGI2 M 15.2+6.8 14+6.6 10+4.1
TXB2  103.8 + 29.2 * 149.2 + 41.2 109.2 + 16.6 *
* diff from CAD but No Ml p  ^  0.05
Table 6 . 6  - Plasma levels of PGI9 metabolites and TXB? (pg/ml) 
in patients with myocardial infarction, coronary 
artery disease but no myocardial infarction and 
controls (means + SD)
6.3 (c) Plasma levels of PGl^ metabolites and TXB^ after rapid
cardiac pacing in patients with chest pain
6.3 (c) (i) Patients and Methods
Using the methodology described in Chapters 3 and 4 we measured 
plasma levels of PGI 2  metabolites and TXB2  in patients before 
and immediately after rapid cardiac pacing.
— 98 —
Twenty four males with ages ranging from 40 - 60 years (mean 51) 
gave their informed consent. Patients being routinely evaluated 
for chest pain with exercise electrocardiography were selected 
provided they did not have valvular heart disease. All patients 
were subjected to rapid cardiac pacing by exercise on an upright 
bicycle ergometer pedalling at a constant speed. A graded 
exercise protocol was used with an initial workload of 300 
kilopond meters/minute (SOOkpm = 50 watts).
A positive exercise test was defined as one producing ST 
depression of 2mm persisting 0.08 seconds after the J point in 
three consecutive cardiac cycles and/or the development of 
typical cardiac chest pain on exertion. All exercise tests were 
performed between 1 0  - 1 1  a.m. and venous blood was taken from 
separate venepuncture sites prior to exercise with the patients 
seated at rest and within one minute of peak exercise. Blood was 
processed and assays performed as described in chapters 3 and 4.
6.3 (c) (ii) Results
The results of plasma PG% 2  metabolite and TXB2  levels in 
patients with positive and negative exercise tests are shown in 
table 6.7 (means + SD),
+ve test (n = 9) -ve test (n = 15)
PRE POST PRE POST
*
PGI2 M (pg/ml) 14.3 + 5.9 20.4 + 7.8 14.8 + 6.1 19.2 + 9.4
TXB2  (pg/ml) 113.3 + 44.1 169.7 + 84.4 128.5 + 31.1 135.8 + 51.6
* different from PRE values P < 0.02
Table 6.7 - Plasma PGI9  metabolites and TXB? before ai^ after 
rapid cardiac pacing in patients with positive and 
negative exercise tests
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6,3 (d) Discussion
Although results did not reach statistical significance plasma 
PGI metabolite levels tended to be increased in patients with 
coronary artery disease compared to age and sex matched 
controls. The results still did not reach statistical 
significance when split up into those patients with and without a 
previous myocardial infarction but this was probably due to the 
smaller numbers. A study using much larger numbers is necessary 
to determine whether levels of PGI^ metabolites are in fact 
higher in patients with coronary artery disease. However the 
tendency of higher levels noted would indicate that higher PGIg 
metabolite levels may be associated with severe vascular disease 
as discussed in 6.1 in Raynaud's syndrome patients and in 
diabetics (6.2). TXB^ levels are significantly higher in
patients with CAD who have had no previous myocardial infarction 
(p <  0.05) than in either patients with previous myocardial 
infarction or controls. This would indicate greater platelet
activation in these patients which could contribute to the
disease. However why patients who have had a previous myocardial 
infarction do not show increased levels of plasma TXB^ is
unclear.
Those patients having a positive exercise test showed a 
statistically significant increase in plasma levels of PGIg 
metabolites (p 0.002). This may be a compensatory mechanism to 
try to produce increased vasodilation in the diseased vessels 
whereas these patients with a negative exercise test were able to 
cope with the increased blood flow produced by exercise without 
the need for this increased vasodilation. Plasma TXB2  levels 
did not show a statistically significant increase in either group
which is in agreement with the results of Hirsh (1983).
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6.4 Conclusions
From these studies it would appear that PGI^ metabolite levels 
are increased in a wide range of severe vascular disease states. 
Whether this is a compensatory mechanism or due to some other 
unknown factor remains unclear.
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CHAPTER 7 - BLEEDING DISORDERS: RELEVANCE OF THROMBOXANE
AND PROSTACYCLIN
7.1 Introduction
Under this heading of bleeding disorders are included a large 
number of conditions which are all characterised by an abnormal 
bleeding tendency. In this chapter the possible role of 
thromboxane and prostacyclin in bleeding disorders will be 
discussed. The results obtained for plasma levels of PGI^ 
metabolites after infusion of l-deamino-8-d-arginine vasopressin 
in von Willebrand's patients will be presented and a patient will 
be described who appears to have a deficiency of thromboxane 
synthetase.
7.2 The Coagulation System
For centuries it has been known that shed blood turns frcm a 
free-flowing liquid into a jelly-like mass. The mechanism by 
which this transformation occurs has been the source of much work 
and wonder and has only recently been elucidated. Plato and 
Aristotle felt that blood clotted because it cooled on exposure 
to air causing its "fibers" to congeal (quoted in Jewett 1892, 
Lee 1952). In 1731 Petit presented the idea that blood clotting 
might stop the flow of blood from wounds. The role of platelets 
in the arrest of bleeding by adhesion to the walls of injured 
vessels was first put forward in 1882 (Bizzozero 18821. Since 
then our knowledge of the coagulation system and its relationship 
to platelet function has developed extensively and is still 
developing. Figure 7.1 shows diagrammatically a scheme of blood 
coagulation.
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FIGURE 7.1 : A scheme of blood coagulation
The factors involved in the arrest of bleeding are complex and 
include:
(i) Contraction of damaged small vessels 
(ii) Plugging of damaged vessels by adhesion and aggregation of 
platelets 
(iii) Coagulation of blood.
An essential feature of haemostasis is the active contraction of 
the capillaries in response to injury. This, together with 
plugging of the bleeding points by the platelet thrombus, allows 
time for the coagulation of the blood to take place. A normal 
platelet count is essential for the arrest of haemorrhage. The 
number of platelets in normal circulating blood is 150 - 250 x
9
10 per litre. Platelets are small round anuclear cells and 
have a diameter about one-third that of red cells. They are 
produced by megakaryocytes in the bone marrow. Platelets have a 
lifespan of about ten days in the blood and do not adhere to 
normal vascular lining or to each other in normal individuals. 
It has been suggested that PGI2  produced by the endothelial 
cells may prevent this adhesion. Damage to the endothelium thus 
allows platelets to contact subendothelial structures especially 
collagen, and initiates platelet adhesion. As well as forming a 
haemostatic plug at the site of injury, platelets contribute to 
blood coagulation by providing the procoagulant activity, 
platelet factor 3 which is not demon^strable in intact platelets 
and is apparently generated during platelet aggregation.
All schemes of blood coagulation distinguish between an intrinsic 
system which involves factors in the blood and an extrinsic 
system which is activated by a tissue factor (or factors) either 
in the laboratory or possibly in the body as a result of tissue
injury particularly in the lungs, placenta or brain.
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Each clotting factor circulates in the plasma as an inactive 
precursor. Once the clotting process is initiated an active 
enzyme is formed which catalyses the next reaction hence the term 
"coagulation cascade" or "waterfall sequence". When blood is 
exposed to tissue extracts factor X is rapidly generated via the 
extrinsic pathway by the interaction of a plasma protein, factor 
VII, and a tissue lipoprotein, tissue factor (or tissue 
thrompoplastin). The intrinsic pathway is initiated by contact 
of blood with a surface other than the normal vascular lining and 
circulating blood cells. Thus, the earliest steps in this 
pathway are called the 'contact phase'. Recently links have been 
found between the extrinsic and intrinsic pathways but the 
physiological significance of these links remains unclear. 
Within the mesh of the fibrin clot formed, red and white cells 
together with platelets are entrapped.
Fibrinolysis is the term used to describe the dissolution of 
these fibrin clots. This is essentially a defense mechanism to 
prevent occlusion of blood vessels.Figure 7.2 shows a simplified 
view of the human fibronolytic system.
INTRINSIC ACTIVATORS EXTRINSIC ACTIVATORS
Surface Hageman 
factor (FXll) 
other agents
plasminogen
inhibitors
Vascular activator 
tissue activators 
urokinase streptokinase
plasmin 4—  inhibitors
I
fibrin
other proteins
Figure 7.2 - A scheme of the fibrinolytic system
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Plasminogen is a plasma protein and is also found to a lesser 
extent in most body fluids. Plasminogen is converted to plasmin 
by the action of specific enzymes: plasminogen activators.
Plasmin may digest fibrinogen, factor V and factor VIII as well 
as fibrin. Plasminogen activators can be classified into 
intrinsic and extrinsic activators. Intrinsic activators are 
endogenous to blood and may convert plasminogen to plasmin when 
blood comes in contact with a foreign surface. All intrinsic 
activators known are much less active than extrinsic activators 
in their ability to activate plasminogen. Extrinsic activators 
are widely distributed in almost all body tissues including 
vascular endothelium and this endothelium derived plasminogen
activator is thought to play an important role in plasminogen
activation because of its close proximity to blood. The
activator urokinase is apparently produced by the kidney and
excreted into urine.
7.3 Role of Thromboxane and Prostacyclin in Bleeding Disorders
It is speculated that since TXA2  produces platelet aggregation 
and vasoconstriction and PGI 2  inhibits platelet aggregation and 
produces vasodilation an imbalance in the production of one or 
other of these substances could be of importance in bleeding
disorders: either a decreased production of TXA2  or increased
production of PGI 2  or both. In contrast to the vast amount of 
literature which has been published on the roles of PGI2  and
TXA 2  in thromboxane vascular disorders there has been very
little work published on their roles in disorders associated with 
a bleeding tendency.
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Brief reports have been published of two cases where a deficiency 
in platelet thromboxane synthetase was presumed (Weiss 1977, 
Mestel 1980). These patients had impaired platelet aggregation 
to arachidonic acid and to prostaglandin G^. Defreyn (1981) 
reported a familial bleeding tendency associated with partial 
platelet thromboxane synthetase deficiency. Three members of a 
family each from successive generations presented with a moderate 
bleeding tendency and a functional platelet defect. The patients 
had reduced serum TXB^ levels and also increased plasma levels 
of 6 -keto-PGFlçC. The commonest bleeding disorders of genetic 
origin are the haemophilias (A and B) and von Willebrand's. I 
report studies on TXB2 /PGI2  balance in these conditions.
7.4 von Willebrand's disease
7.4 (a) Introduction
In 1926 von Willebrand first described a congenital haemorrhagic 
disorder which he observed in several members of one family. He 
found 23 cases among 6 6  members of the family. The condition was 
found in both men and women and several children from the family 
had died prematurely from intestinal bleeding or following minor 
injury, von Willebrand found that patients suffering from the 
disease had a prolonged bleeding time, a normal clotting time and 
normal platelet count. Their platelets were morphologically 
normal. The disease was first called pseudo-haemophilia because 
of the similarity to that disorder. The disease has been shown 
to be inherited as a simple autosomal dominant.
— 106 —
Later studies have shown that platelet retention by a column of 
glass beads is abnormal in von Willebrand's disease (Salzman 
1963) as is ristocetin induced platelet aggregation (Howard 1971) 
and ex vivo interaction of platelets with the subendothelial 
surface of segments of blood vessels (Tschopp 1974). von 
Willebrand's disease can now be subdivided into at least four 
major subgroups (Types 1-4).
Type I has a reduction in all the factor VIII von Willebrand 
factor complex activities. Type II is characterised by 
discordant reductions in the factor VIII von Willebrand factor 
complex activities, with VIII : RCo being more reduced than VIII 
: C or VIII R : Ag. At least three subgroups have been
recognised. In type I la the patients may have mild to severe 
clinical symptoms with inheritance being most compatible with 
autosomal dominant transmission. Ristocetin-induced aggregation 
of platelets in platelet-rich plasma is reduced as is FVIIIiRCo. 
Platelets from patients of type Ilb have the ability to aggregate 
in response to much lower concentrations of ristocetin than do 
normal platelets. Type lib also appears to be inherited as an 
autosomal dominant. As technology advances various new subtypes 
are being described.
There is also a group of patients who clinically have a bleeding 
disorder similar to von Willebrand^s disease but since the defect 
in this group is thought to be primarily in the platelet and not 
in the von Willebrand factor, it has been termed platelet-type or 
pseudo Von Willebrand's disease (Miller 1982). With the 
information available to date it is impossible to identify with 
certainty the precise abnormality in any of the types of von 
Willebrand's disease.
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7.4 (b) l-deaminç>-8-d-arginine vasopressin (DDAVP)
and von Willebrand's disease
7.4 (b) (i) Introduction
DDAVP has been used effectively to treat bleeding episodes in 
patients with von Willebrand's disease (Lowe 1977, Mannucci 1977, 
Ockelford 1980, Warrier 1983). Uremic patients with 
haemmorrhagic tendencies have also been shown to correct their 
bleeding tendency after DDAVP (Mannucci 1983). DDAVP stimulates 
the vascular endothelium to release FVIIIR : Ag and plasminogen 
activator (Cash 1974).
It has been shown that, after an infusion of FVIII in haemophilia 
there is increased platelet aggregation to ADP and also a rise in 
the number of circulating platelet aggregates (Grigani 1979). 
However when endogenous FVIII levels are increased after an 
infusion of DDAVP this increase in circulating platelet 
aggregates is not observed (Belch 1982). This could be explained 
if DDAVP also stimulated endothelial cell release of PGI^, 
which could also explain the flushing observed during DDAVP 
infusion.
There has been controversy in the literature as to whether or not 
DDAVP does in fact stimulate release of PGI^ from endothelial 
cells. Our laboratory previously published evidence showing that 
plasma levels of 6 -keto-PGFl oC were raised following DDAVP 
infusion (Belch 1982). However studies with an inproved assay 
showed that the levels of 6 -keto-PGFl cC. were unrealistically 
high, probably due to extraction methods used (see 3.7). Barrow 
(1983) has since reported that DDAVP infusion did not increase 
circulating levels of PGI^ or TXA^ in normal volunteers.
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They measured absolute values of 6 -keto-PGFlçCusing negative ion 
chemical ionisation mass spectometry. Using an umbilical vein 
perfusion model Barnhart (1983) could find no increase in levels 
of 6 -keto-PGFloCwhen measured by R.I.A., after DDAVP. All these 
studies are based on measurement of 6 -keto-PGFloC . After the 
development of our assay for PGI^ metabolites we repeated our 
earlier work measuring plasma levels of PGI2  metabolites before 
and after infusion of DDAVP using this inproved methodology. We 
also studied haemophiliac patients and patients with von
Willebrand's disease receiving infusions of DDAVP.
7.4 (b) (ii) Patients and Methods
Seven normal healthy subjects, 11 severely affected haemophiliacs 
with baseline factor VIII coagulant activity (FVIIIc) or factor 
IX less than 1% (7 with haemophilia A and 4 with haemophilia B) 
and 8  patients with von Willebrand's disease (7 with type 11a and 
1  with type 1 ) were studied after informed consent had been
obtained. No subject had taken any drugs for a minimum of two 
weeks previously. Venous blood was collected as described in
chapter 3.7 for measurement of plasma levels of PGI 2
metabolites and TXB2 .
DDAVP was then given intravenously at a dose of 0.3ug/kg body
weight over 15 minutes using a Vickers Treonic IP3 syringe punp. 
The volume of infusion was kept constant at 25 ml for all
subjects by making up the DDAVP in 0.9% sodium chloride. A 
further blood sairple was taken, as before, immediately after
termination of the infusion. Plasma PGl^ metabolites and
TXB2  levels were measured by R.I.A. as described in chapters 3 
and 4 respectively.
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7.4 (b) (iii) Results
The results are shown in Table 7.1
The basal levels of PGI^ metabolites were significantly lower 
in the von Willebrand patients than in the normals and 
haemophiliacs. There was no difference in the basal levels of 
PGIg metabolites between the normal and haemophiliac groups. 
All three groups showed a significant increase in PGI 2  
metabolites following infusion of DDAVP. No significant 
difference in the per cent increase was found in the three 
groups. The post-DDAVP levels of PGI2  metabolites were still 
significantly lower in the von Willebrand group than in the 
normal group.
All the normal volunteers and the haemophiliacs showed marked 
facial flusing during the infusion but this was not observed in 
any of the von Willebrand subjects. There was no statistically 
significant difference in basal levels of plasma TXB2  between 
any of the groups nor were there any statistically significant 
differences post - DDAVP. Although the results do not form part 
of this thesis FVIIIR:Ag, FVIIIC and plasminogen activator are 
included in this table to substantiate the theory of endothelial 
cell stimulation by DDAVP. Methodology for these assays is as 
described by Greer et al (1986).
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Normal Haemophilia vWd
pre-
DDAVP
post-
DDAVP
pre-
DDAVP
post-
DDAVP
pre-
DDAVP
post-
DDAVP
PGI2 M 17.5 29.0** 16.3 2 2 .6 ** 11.5**** 15.2******
pg/ml +2.4 +9.0 +5.7 +9.8 +1.7 +4.0
TXB2 145.0 195.0 108.0 118.0 92.0 117.1
pg/ml +38.2 +52.6 +33.0 +32.0 +40.7 +97.4
FVIIIR : Ag 71.1 132.0** 118.6 185.6** 45.1 95.5**
% normal +30.4 +30.8 +30.4 +53.4 +18.7 +37.0
pool
FCIIIc 139.6 334.3** _ 41.5 129.9**
% normal +41.9 +82.6 +15.8 + 67.2
pool
FPLA 60.8 97.1* 52.7 77.8*** 68.4 96.5**
mm^ +11.5 +28.0 +14.3 +18.4 +25.6 +29.7
n 7 1 1 8
Male:female 2:5 1 1 : 0 2 : 6
*p4: 0.05 :**p^ 0.02 0.005 compared with pre-DDAVP measure­
ment for same group;****p^^0.005 compared to pre-DDAVP measure­
ment for normal and haemophilia group:****p 0 . 0 0 2  compared to
post-DDAVP measurement for normal group.
Table 7.1 - Effect of DDAVP infusions on plasma TXB? and 
PGI9 metabolites (mean + SD)
7.4 (b) (iv) Discussion
These results confirm our previous findings that DDAVP stimulates 
PGI^ production in normal and haemophiliac patients. It has 
been shown by Ritter (1983) that physical stimulation of vascular 
endothelium can release PGI2 *
It has recently been shown that production of PGI2  by cultured 
endothelial cells depends on the number of platelets in the 
flowing blood and also on the wall shear rate (Grabowski 1984).
- Ill -
Deficiency of von Willebrand factor results in shear dependent 
reduction in platelet adhesion to the vessel wall (Weiss 1978). 
It is possible therefore that the lower basal and post DDAVP 
levels of PGI^ metabolites found in von Willebrand's disease 
may be due to decreased platelet interaction with the endothelium 
resulting from von Willebrand factor deficiency.
Although TXB^ tended to be lower in vWd, the difference was not
statistically significant. Since patients with VWd have normal
platelet aggregation to physiological stimuli and normal
arachidonic acid metabolism, it is perhaps not surprising that 
TXB^ is not reduced. The mechanism for the action of DDAVP on 
PGI2  production is not entirely clear. Previous in vitro 
studies have shown DDAVP to have a direct Smulatory effect on 
PGI2  production from arterial tissue (Belch 1982) while there 
is mounting evidence that the effect of DDAVP on FVIIR : Ag
release is mediated via a secondary messenger (Cash 1978, Booyse
1981). In the absence of any change in TXB^ levels following 
DDAVP, the stimulatory effect on PGI 2  production may be 
mediated through an endothelial cell receptor rather than a 
general activation of the arachidonic acid cascade.
The failure of the vWd subjects to flush is also of interest, 
since this general vasodilatation is seen in normal and 
haemcphilic subjects and has been shown to be abolished by 
aspirin (Belch 1982). It is likely therefore to be due to the 
potent vasodilator action of PGI2  or failure to reach a "flush 
threshold", as the vWd subjects had lower post-DDAVP levels of
PGI2  than normal subjects.
- 112 -
7.4 (c) Perfusion of umbilical artery with DDAVP
7.4 (c) (i) Introduction
Previous work from our laboratory showed evidence of PGI release 
from rat aortic rings after incubation with DDAVP (Belch 1982). 
However using an umbilical vein perfusion model Barnhart (1983) 
was unable to detect a similar increase. In order to try to 
confirm our previous work using difference methodology we used 
our umbilical artery perfusion model described in 3 .1 1 .
7.4 (c) (ii) Methods
The umbilical artery perfusion model was set up as described in 
3.11 using a normal umbilical artery. DDAVP 10~^M was perfused 
through the vessel after prior perfusion with 650 mis of Ringer's 
buffer. Fractions were collected and stored at -70°C for 
R.I.A. for PGI^ metabolites as described in 3.7.
7.4 (c) (iii) Results
The results of the perfusion of a normal umbilical artery with 
DDAVP on levels of PGI2  metabolites are shown in figure 7.3 
Levels of PGI^ metabolites showed an increase frcm the level 
of 100 pg/ml prior to the perfusion of DDAVP to a peak level of 
580 pg/ml after DDAVP was perfused.
7.4 (c) (iv) Discussion
This experiment although performed only on one occasion does 
confirm our earlier work using rat aortic rings in which we 
showed increased levels of 6-keto-PGFl from the rings after 
incubation with DDAVP (Belch 1982). Together with the perfusion 
studies in normal volunteers it would appear that DDAVP acts as a
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general endothelial cell stimulant, stimulating release of PGi^ 
as well as FVIIIC, FVIIIR : Ag and plasminogen activator.
However the underlying mechanisms for this remain unclear.
7.5 Report on Patient with a possible thromboxane synthetase 
deficiency
7.5 (a) Introduction
Thromboxane synthetase is the enzyme that converts the cyclic 
endoperoxides into thromboxane A . To date only two families 
with a deficiency of this enzyme have been reported (Mestel 1980, 
Defreyn 1981). The platelets from these patients do not form 
TXA^ as normal platelets do, even when they are supplied with 
the cyclic endoperoxides. Defreyn noted increased levels of 
plasma 6 -keto-PGFl however their normal levels of 181 _+ 46 pg/ml 
would appear to be very high thus leaving their assay methodology 
open to question. However the increased levels of 6 -keto-PGFl 
could be due to the cyclic endoperoxides produced by the platelet 
gaining access to the endothelium where they are converted to 
PGI2 . We report results on one patient who would appear to 
have a possible deficiency of thromboxane synthetase.
7.5 (b) Patient and Methods
Our patient suffered heavy bleeding after all dental extractions 
and also had mennhoragia. She had post-par turn haemorrhage after 
all three deliveries and had a probable secondary haemorrhage 
after a tonsillectomy at 21 years of age. She had however 
undergone an apparently uneventful appendectony. She had a 
normal thrombin time, prothrombin time and activated partial 
thromboplastin time. Factor FVIIIC and factor VIHR : Ag were
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within the normal range. Aggregation to ristocetin and ADP were 
normal but collagen aggregation was reduced. She had a bleeding
time of 14 minutes 15 seconds. Using the method described in
Chapter 4 we measured serum TXB^ thromboxane generation in
response to aggregation with collagen 4ug/ml and serum TXB2  in
bleeding time blood. We also measured plasma PGI^ metabolites 
as described in 3.7.
7.5 (c) Results
T h e results are shown in table 7.2.
Patient Normal
Serum TXB2  (ng/ml) 12 311 + 112 SD
Serum TXB2  in BT blood (ng/ml)
(average of first two minutes) 4 400
TX generation 12 118 hh 30 SD
Plasma PGI2  metabolites (pg/ml) 14 13.1+1.2
Table 7.2 - Results of thromboxane levels in patient with 
suspected thromboxane synthetase deficiency
(d) Discussion
The results of serum TXB^ and serum TXB^ in bleeding time 
blood are very much lower than our normal levels. Thromboxane 
generation in response to aggregation with 4 ug/ml collagen was 
also much reduced. However since the patient had reduced 
response to collagen aggregation, when this patient returns a 
blood sample should be taken to measure the thromboxane 
generation in response to ADP.
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since ADP platelet aggregation was normal we would then be able 
to measure the amount of thromboxane generated in response to 
maximal aggregation and this was not true for collagen. There is 
no evidence of increased levels of PG% 2  metabolites. There is 
much more study of this patient and her family necessary to show 
that this is a case of thromboxane synthetase deficiency. 
However such low levels of serum TXB2  and serum TXB2  from 
bleeding time blood have not been seen in any other patients we 
have studied except when treated with cyclo-oxygenase inhibitors 
or thromboxane synthetase inhibitors.
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CHAPTER 8  - PROSTACYCLIN AND THROMBOXANE IN PREGNANCY 
AND RELATED CONDITIONS
8.1 Introduction
The maternal and foetal circulations are characterised by low 
vascular resistance and vasodilation which may or may not be due 
to prostacyclin. Tissues such as myometrium (Bamford et al 1980) 
decidua, chorion and amnion (Mitchell et al 1978) and trophoblast 
(Rakoczi et al 1983) all pregnancy associated tissues, have been 
shown to produce PGI^ in vitro. Various studies (Mitchell et
al 1978, Harper et al 1983, Nikolaides et al 1983, Makila et al
1984) have reported PGI^ production by placental tissues. 
However Dembele-Duchesne et al (1982) claim that this
anti-aggregator y factor is neither PGI^ nor a PGIg
metabolite. Various studies using human umbilical vessels and 
different in vitro models (Hamberg et al 1979, Remuzzi et al 
1979, Ritter et al 1982) and Stoel et al 1982) have reported 
PGI2  from arteries and veins with arterial tissue having the 
ability to produce the greater amounts (Kent 1981). Increased 
release of PGI^ has also been demonstrated from the uterine 
vessels of pregnant women (Bussolino et al 1980). This ability 
to produce PGI2  by both foetal and maternal tissues may be of
importance in normal pregnancy and may be implicated in some
pathological conditions of pregnancy. The results of studies 
measuring levels of 6 -keto-PGFl ©i, the stable hydrolysis product 
of PGI2 ' maternal peripheral blood have been conflicting.
Lewis et al (1980) showed an increase during late normal
pregnancy and the puerperium whereas Bolton et al (1981) showed 
that levels reached a peak at 18-22 weeks of pregnancy with mean
values from 26-42 weeks being significantly lower.
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In order to carry out any study of PGIgM and TXB^ levels in 
pathological disorders of pregnancy it is necessary to have 
normal levels with which to do conparisons. The aim of our first 
study therefore was to determine the values both of PGI^ and of 
TXA^ metabolites throughout normal pregnancy and the puerperium.
8.2 Plasma PGI^ metabolites and TXB^ in normal pregnancy 
and the puerperium
8.2 (a) Patients and Methods
The study included 155 women; 44 normal non-pregnant, 29 in the 
first trimester of pregnancy, 31 in the second trimester, 29 in 
the third trimester and 21 on the third day after delivery. All 
pregnancies were uncomplicated and no subject had taken 
aspirin-like drugs for at least two weeks prior to sampling. 
Blood sampling and RIA's for PGI^ and TXA^ metabolites were 
performed as already described in 3.6 and 4.3 respectively.
8.2 (b) Results
Results for PGI2 M are shown in Figure 8.1, and for TXB^ in 
Figure 8.2. We found a significant difference in PGIgM levels 
in the first trimester ( p <  0 .0 1 ) when compared with those in the 
non-pregnant group. While there were no significant differences 
between non-pregnant values and those in the second or third 
trimesters, we noted a trend towards lower concentrations of 
PGIgM on the third postnatal day, but this did not reach 
significance. Levels of PGI2 M were significantly lower in the 
second and third trimester than in the first trimester group. 
There was a progressive reduction in plasma TXB2  concentrations 
from the second trimester, through the third trimester and into
the puerperium. Table 8 .1 gives a fuller statistical analysis.
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Figure 8.1 : Plasma PGI^ metabolite levels in normal pregnancy
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Figure 8.2 Plasma TXB^ levels in normal pregnancy
Non 1st 2nd 3rd
pregnant trimester trimester trimester Postnatal
***
PGI2 M 15.9(0.68) 19.9(0.96) 15.5(1.05) 16.4(1.22) 13.6(1.99)
TXB2  142(4.9) 131(14.2) 133(14.9)* 123(10.7)** 119(6.3)***
n 44 29 31 29 21
*** p <  0.01, ** p <  0.02, * p <0.05 compared with non pregnant, 
*** p <  0.05, ** p <  0.01, compared with 1st trimester 
Results are mean (SEM) values
Table 8.1 - Plasma levels of prostacyclin metabolite (PGI9 M and 
thromboxane B9 (TXB9 ) in non-pregnant women, the 
three trimesters of pregnancy and the puerperium
8.2 (c) Discussion
Despite using larger numbers we did not confirm the work of Lewis 
et al (1980) v^o showed a higher concentration of 6 -keto-PGF^o^ 
in the late pregnancy and the puerperium. Neither could we
confirm the work of Bolton et al (1981) as our peak levels of
PGI2 M occurred in the first trimester, and not in mid-pregnancy 
as they reported, although they did not record levels before 14 
weeks gestation.
We found a significant difference in the first trimester compared 
with values in the non-pregnant and second and third trimesters. 
Ihis early increase may be involved in the physiological
vasodilation and insensitivity to angiotensin II (Grant et al 
1973) which are characteristic of early pregnancy.
It has recently been shown that trophoblast from early pregnancies 
has a high capacity to synthesise PGI2  and it has been suggested 
that colonisation of maternal blood vessels by trophoblast is
facilitated by PGI2  which may prevent platelet aggregates from 
halting this process (Lewis 1982). This theory might explain our 
findings of elevated PGI2 M levels in early pregnancy.
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Failure of this response may possibly result in threatened or 
spontaneous abortion, and may even lead to fetal growth 
retardation in later pregnancy, a condition where low PGI^ 
metabolites have previously been recorded (Jogee et al 1983; 
Stuart et al 1981).
Theoretically one might expect high levels of PGI in late 
pregnancy, due to the potential for increased production from the 
uterus and fetoplacental circulation unit. We have not found any 
increased levels at this stage.
This may be explained by the findings of Remuzzi et al (1981), who 
found a reduced level of prostacyclin-stimulating factor in late 
normal pregnancy, possibly a homeostatic mechanism. Since the
capacity to produce PGI^ is increased at this stage, less
prostacyclin-stimulating factor is required, and PGIg levels 
would remain constant as we have described. Conversely v4ien the 
ability to produce PGI^ is low, as in pregnancy-induced
hypertension, prostacyclin-stimulating factor rises in an attempt 
to increase PGI^. This change has also been noted by Remuzzi et 
al (1981). In the postnatal group we observed a trend towards 
reduced levels which contradicts the work of Lewis et al (1980). 
Our sampling was performed only on the third postnatal day, while 
Lewis et al (1980) sampled between the first and seventh postnatal 
days. If many of the samples were obtained soon after delivery 
they may have a high 6 -keto-PGF^@C level due to vascular 
injury. Also, increased in-vitro production of 6 -keto-PGF^oC 
from sheep cervical tissue taken at parturition has been reported 
(Ellwood et al 1981). Since the fetoplacental unit, which has 
enormous capacity to synthesise PGI^ is removed at birth, a
reduction in 6 -keto-PGF^<C levels postnatally might be expected.
- 120 -
We have observed a progressive fall in plasma TXB^ 
concentrations through pregnancy and into the puerperium. ihis 
may reflect increased platelet stability, or the diversion of 
TXB^ precursors into the formation of other prostaglandins, such 
as PGD^ or PGE^. Other possible explanations of this may be 
related to a change in activity of thromboxane synthetase or 
decreased substrate availability, but further studies are required 
to elucidate this.
We noted several very high levels of TXB^ (Figure 2) which we 
cannot explain; they were levels normally associated with 
traumatic venepuncture or haemolysis, but we discarded all samples 
in which either of these problems were apparent. We would suggest ' 
that these may be due to subclinical trauma at the time of  ^
venepuncture with resultant platelet activation. '
8.3 Pregnancy Induced Hypertension
8.3 (a) Introduction
Approximately 10 per cent of all pregnancies are complicated by 
some degree of hypertensive disease. Ihe level of blood pressure 
is closely related to foetal well-being and if the blood pressure 
is persistently elevated during pregnancy there is an associated 
increase in perinatal mortality. Ihe pathogenesis of pregnancy 
induced hypertension (PIH) is not yet fully understood but some 
workers suggest the involvement of prostaglandins: PGI2  has
been shown to be produced by the placenta (Carreras et al 1981) 
and as it is not metabolised in the lungs (Gerkens et al 1978) , 
placentally produced PGI2  could have local and systemic effects.
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Downing et al (1980) have found PGI synthetase activity to be 
the same in cords from normal and hypertensive pregnancies however 
the cords from pregnancies complicated by hypertension contained 
less of the enzyme. Carreras et al (1981) compared PGI 2  
production by umbilical arteries and veins found decreased 
production in hypertensive patients. The production of PGI2  
from placentae obtained from toxaemic pregnancies were found to 
produce approx one third of that produced by placentae from 
uncomplicated pregnancies (Walsh et al 1985). Ihis agreed with 
earlier work by Lewis et al (1981) who had found decreased 
production by both placental and umbilical vessels. When
measuring plasma levels of 6 -keto-PGF^«>d., the stable hydration 
product of PGl2 f conflicting reports appear in the literature. 
Ylikorkala et al (1981) report no difference between pre-eclamptic 
and normal pregnancies. Whereas Yamaguchi et al (1985) and Lewis 
et al (1980) both report lower levels in pre-eclamptics compared 
to normal patients. As was discussed in chapter 3, the
methodological problems associated with the assay of plasma levels 
of 6 -keto-PGF^ make comparisons between different groups 
difficult. Lewis et al (1981) also relate falling levels of 
6 -keto-PGFj^ oC to the worsening of the disease. Beneficial 
effects of PGI2  infusions have been reported (Fidler et al 1980). 
Thromboxane has also been implicated in the etiology of PIH 
(Ylikorkala et al 1980, 1981). High levels of TXA2  would cause 
increasing blood pressure and falling platelet count which are 
both features of fulminating pre-eclampsia. It would seem
therefore that the interaction in the roles of PGI2  and TXA2
are important and worth investigation in this disease.
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8.3 ( b) A longitudinal study of plasma PGI^M and TXB^levels in
normal and hypertensive pregnancies
8.3 (b) (i) Introduction
Bolton (1981) has produced the only prospective longitudinal sutdy 
of maternal plasma 6-keto-PGF^*C levels. Ihey found that in 12 
normal pregnancies levels peaked between 18 and 2 2  weeks 
gestation. However they did not take samples during the first 
trimester nor did they measure TXB^ levels. Various cross 
sectional studies have been published giving conflicting results
as discussed in 8 .1. We performed a prospective longitudinal
study of PGI^ metabolites and TXB^ in maternal plasma 
throughout normal pregnancy.
However six of our fourteen randomly selected patients 
subsequently became hypertensive and we were thus able to study 
PGI2  metabolites and TXB^ in both normal and hypertensives.
There was no apparent reason for this high incidence of pregnancy 
induced hypertension in our randomly selected group. Ihe normal 
incidence of pregnancy induced hypertension in our population is 
5-10% and the high incidence appears to be totally coincidental.
8.3 (b) (ii) Patients and Methods
Fourteen randomly selected primigravidae patients were selected
who had no previous history of hypertension and no other medical 
disorder. None of the subjects took any non-steroidal anti 
inflammatory drugs for at least two weeks prior to blood 
sampling. Samples were taken in the first trimester between 9 and 
12 weeks gestation; in the second between 17 and 24 weeks 
gestation and in the third between 32 and 36 weeks gestation.
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In the patients who became hypertensive further samples were taken 
where possible between 36 weeks and term. Mild to moderate 
pregnancy induced hypertension was defined as a persistent 
diastolic blood pressure of 90mm mercury. None of the six who 
became hypertensive developed significant platelet consumption or 
proteinuria. All the patients had vaginal deliveries and all 
delivered healthy babies of normal birth weight.
Blood sampling and radioimmunoassay was performed as described in 
chapters 3 and 4.
3 (b) (iii) Results
Figure 8.3 shows the plasma PGI^ metabolite and TXB^ levels in
normal pregnancies. PGI2  metabolite and TXB2  levels were
significantly lower in both the second and third trimesters than 
in the first.
Figure 8.4 shows the plasma PGI2  metabolite and TXB^ levels in
hypertensive pregnancies. Ihis group showed no significant 
differences in PGI2  metabolite levels in the three trimesters 
also levels were not significantly different from the normal 
group. However all the hypertensive patients developed 
unrecordable levels of < 5pg/ml in the third trimester when they 
were hypertensive. None of the normal group developed
unrecordable levels at any stage.
As with the normal group TXB2  levels decreased significantly in 
the second and third trimesters when compared to the first. There 
were also no significant differences at any stage when compared to 
the normal group.
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8.3 (b) (iv) Discussion
In 5 out of the 6  hypertensive patients the hypertension had 
developed prior to the sample which gave unrecordable levels. 
Therefore it was impossible to determine which came first: the
hypertension or the unrecordable levels of PGI_ metabolites. 
One patient however had a third trimester unrecordable level 
prior to the onset of hypertension and levels remained 
unrecordable thereafter. These results are in agreement with 
work published by Lewis (1981) who reported falling levels of 
plasma 6 -keto-PGFjoc in one patient when she developed 
hypertension. Goodman (1982) measured urinary levels of PGI^ 
metabolites and found significantly reduced levels in 
hypertensive patients compared to controls.
Since one patient showed unrecordable levels of PGI2  
metabolites prior to the development of hypertension it is 
possible that this may be a means of detecting the onset of 
hypertension.
However much more work must be carried out in order to prove 
this. TXB2  levels were not significantly different in the
hypertensive group when corrpared to control anc^ therefore would 
not appear to be related to pregnancy induced hypertension.
The results in the normal group, although numbers are small, 
agree with our cross sectional study (8 .2 ).
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♦3 (c) Umbilical artery perfusion model: comparison of vessels
from normal and hypertensive pregnancies 
.3 (c) (i) Materials and Methods
We obtained umbilical cords from two patients suffering from 
pregnancy induced hypertension defined as persistent diastolic 
blood pressure of > 90mm of mercury. One patient had underlying 
renal pathology which could lead to hypertension but she had 
shown no signs of this before becoming pregnant.
The arteries were dissected and the perfusion model set up as 
described in 3.11. After initially perfusing with 150 - 200 mis 
of Ringer's buffer, 5 mis of normal platelet poor plasma was
perfused through the artery then perfusion with Ringer's buffer 
was continued. 5ml fractions were collected and stored at
-70^C for RIA of PGIg metabolites as described in 3.7.
.3 (c) (ii) Results
The results we obtained from the two hypertensive cords were
compared with the same experiment we had previously done using an 
artery from an uncomplicated pregnancy. We have repeated the 
same experiment on normal umbilical arteries on several occasions 
and an increase in the levels of PGI2  metabolites after 
perfusion of normal platelet poor plasma is always seen. However 
as can be seen from the results shown in figure 8.5 neither of 
the arteries from the hypertensive patients showed any 
significant increase in levels of PGI2  metabolites.
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.3 (c) (iii) Discussion
Since this is the result of only two experiments it is necessary 
to repeat the perfusion on many more arteries from pregnancies 
complicated by pregnancy induced hypertension. It has been shown 
that normal plasma contains a factor capable of stimulating 
endothelial cell producion of PGI2  (McIntyre 1978, Remuzzi 
1979a, Defreyn 1980) and we have shown (3.11 c) that using our 
umbilical artery perfusion model we can stimulate PGI^ 
production using platelet poor plasma. However in both arteries 
studied from complicated pregnancy this stimulation of PGI^ 
production was not seen. It would seem therefore that our 
finding of unrecordable levels of PGI2  metabolites in 
hypertensive pregnancies (8.3) could be related to defective 
endothelial cell production.
.4 Labetalol in Pregnancy Induced Hypertension 
,4 (a) Introduction
Labetalol is a combined «C and ^ adrenergic blocking agent which 
has been used extensively in the treatment of pregnancy induced 
hypertension (PIH). Labetalol has been shown to be of value in 
controlling the blood pressure with resulting improved foetal 
survival (Michael et al 1979, Lamming et al 1979, Walker et al
1982). Labetalol also reduces prot^uria (Lamming et al 1979, 
Walker et al 1982) and platelet consumption (Walker et al 1982a) 
as well as having a vasodilator action. In patients with severe 
pregnancy induced hypertension with active platelet consumption, 
thrombocytopenia and microangiopathic haemolytic anaemia, 
treatment with labetalol reverses these parameters returning the 
platelet count to normal (Walker et al 1982b).
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The mechanism behind the action of Labetalol is unclear. We have 
performed studies to examine the in vitro affect of Labetalol on 
PGl^ and TXA^ production.
8.4 (b) Affect on thromboxane and prostacyclin production in whole
blood of incubation with Labetalol
8.4 (b) (i) Introduction
There have been several studies published which show that 
p-adrenoceptor antagonists can reduce platelet aggregation and 
TXA^ production from platelet rich plasma stimulated by 
thrombin and arachidonic acid. (Heinroth 1983, Brandt 1984, 
Mehta 1983). Most of these studies however have concentrated on 
propanolol which is a p^, p^ blocker. There has however been 
little work on the effect on whole blood. This may be a more 
physiological method to use since it leaves the platelets in 
contact with red and white cells which can influence platelet 
behaviour by release of ADP (Small 1982) and PGI^ (Orlandi
1985) respectively.
8.4 (b) (ii) Method
Blood was obtained without stasis from healthy volunteers who had 
taken no drugs for a minimum of two weeks previously. 1  ml 
aliquots were placed into previously prepared glass tubes 
containing either Labetalol in varying concentrations or its 
vehicle. The tubes were immediately put to incubate at 37°C 
for one hour. The serum was separated by centrifugation at 2500g 
for 15 minutes at 4^C. Aliquots were stored at -70°C for RIA 
for PGI2 M and TXB2  as described in Chapters 3 and 4 
respectively. We had previously shown that inhibition of PGI2 M
and TXB2  could be measured using this technique (see 5.3).
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Control n = 8
1 . 0 n = 8
1 0 . 0 n = 8
1 0 0 . 0 n = 8
* p < 0.05
** p < 0 . 0 2  (
8.4 (b) (iii) Results
Concentration of Serum TXB2  Serum PGI2 M
' ' ' 1  (ng/ml) pg/ml
117.8+12.5 413.8+
99.4 + 27.7 * 340.0 + *
74.6 + 30.3 ** 303.8 + **
48.0 + 21.2 ** 251.2 + **
Table 8.2 - Levels of serum TXB9 and PGI9 M (mean + SD) 
after incubation with Labetalol
8.4 (c) Thromboxane generation - prior incubation with Labetalol
The reduction observed in PGI^M and TXB_ in whole blood 
allowed to clot with the addition of Labetalol was in response to
(I.
an ^dogenous stimulus i.e. thrombin. We also studied the amount / 
of TXB^ generated in response to an exogenous aggregating 
agents, in this case collagen at a final concentration of 4 
/ig/ml. The method used was the method described for thromboxane 
generation in 4.6 but the PRP was incubated with lOCjpl of either 
saline or labetalol for 5 minutes prior to the addition of the 
aggregating agent.
Table 8.3 shows results of TXB^ generation after prior 
incubation with Labetalol
Cone of Labetalol (jug/ml) TXB9 (ng/ml)
Control n = 10 105.5 + 7.1
1  n = 10 78.5 + 10.8 *
12.5 n = 10 69 + 16.5 **
25 n = 10 52 + 15.2 *
* p 0 . 0 0 1
** p <  0.005 different from control values
Table 8.3 - TXB? generation levels after prior incubation with 
Labetalol (Means + SD)
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8.4 (d) PGI^Production from umbilical artery perfusion model
treated with Labetalol 
We used our umbilical artery perfusion model described in chapter 
3.11 to measure levels of PGI^ metabolites after perfusion with 
Labetalol. Initial experiments using rat aortic rings to detect 
release of a PGl2 “like substance by bioassay proved 
inconclusive. Because of the limitations of the artery ring 
method as discussed in 3.11 we decided to use the more 
physiological artery perfusion model. If pregnancy induced 
hypertension is mediated partly through PGI2  deficiency 
(Bodzenta 1980) stimulation of PGI2 release from the 
endothelium would help to explain the beneficial effects 
described after treatment with Labetalol.
25 mis of Labetalol (100 jag/ml) in Ringer's buffer were perfused 
through the vessel after prior perfusion with 175 mis of buffer 
alone. The artery was in two halves with one half acting as 
control. 5ml fractions were collected and stored at -70^C 
until RIA for PGI2  metabolites as described in Chapter 3.7. 
The results we obtained are shown in figure 8 .6 .
8.4 (e) Discussion
Inhibition of both TXB2  and PGI2 M was observed when whole 
blood was left to clot with Labetalol. This would suggest that 
the inhibition may be due to a block in the arachidonic acid 
pathway at either the phospholipase or the cyclooxygenase steps. 
The inhibition of TXA may be clinically beneficial in view of 
the evidence implicating TXA2  in vascular disease (Cocker 1983, 
Robertson 1981, Hirsch 1981, Cocker 1981). However the 
inhibition of PGI 2  is potentially harmful in view of its 
vasoprotective effect. This is especially true in toxemic
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FIGURE 8.5: UMBILICAL ARTERY PERFUSION WITH LABETALOL 10(^g/ml
pregnancies in which reduced PGI^ production has been 
implicated (Remuzzi 1980, Walsh 1985). Any further reduction 
therefore could worsen the disease. However the reduction in 
serum PGI^ levels was only an average of 3 9 .2 % whereas serum 
TXB2  levels fell by an average of 59.3% after incubation with 
Labetalol. Our initial study using rat aortic rings suggested 
that Labetalol stimulated release of a PGI^ like substance. 
When Labetalol 100 jug/ml was perfused through our umbilical 
artery there was no evidence of inhibition of vascular 
production there was in fact a slight increase in PGI2  
metabolite levels. However this experiment must be repeated 
using more umbilical arteries.
It has been shown by Campbell (1981) that propranalol had no 
effect on PGI^ production from cultured vascular endothelial 
cells. We showed however that propranalol inhibited serum PG% 2  
after incubation with whole blood (Greer 1985). It may be 
therefore that vascular PGLg production is less sensitive to 
the effect of Labetalol and other adrenoceptor antagonists such 
as Labetalol than is PGI2  production by whole blood which may 
be affected by white cells. Further work on white cells PGI2  
production must be done before this can established. Whether or 
not these observations on TXA2  and PGI2  production are of any 
clinical significance must be established by further in vivo 
studies.
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8.5 Amniotic Fluid PGI^ metabolites   ^ :------
8.5 (a) Introduction
Many pregnancy associated tissues such as the uterus, decidua, 
placenta and fetal membranes and vessels produce PGI^ and 
TXA2  in vitro (Tuvemo 1980). Consequently these tissues could 
be a source of the increased production of these prostanoids 
during gestation. Since the amniotic fluid is in contact with 
many of these tissues its concentrations of PGI^ metabolites 
and TXB2  could reflect intrauterine production of PGI2  and 
TXA2  in vivo. Previous studies have found levels of 
6 -keto-PGFlpC in amniotic fluid at term pregnancy to be 444 pg/ml 
and TXB2  100 pg/ml (Mitchell 1978, 1979). Ylikorkala et al 
(1981) found normal levels of 6 -keto-PGFloC of 171.8 +9. 0  and 
TXB2  35.0 + 5.7 at approximately 38 weeks of pregnancy. All 
samples they tested from both normal and complicated pregnancies 
had detectable amounts of both 6 -keto PGFloC and TXB2 . Roy et 
al found detectable levels of PGI2  metabolites in amniotic 
fluid in the second trimester with a mean of 34 + 17 (SD) pg/ml 
(Roy 1984). As the levels of 6 -keto-PGFloC , all measured by 
radioimmunoassay, varied considerably in the published work we 
decided to use our radioimmunoassay to measure amniotic fluid 
levels of PGI2 M in amniotic fluid. Ihe involvement of PGI2  
in pre-eclampsia and other pregnancy complications characterised 
by fetoplacental vasoconstriction is poorly understood and to be 
able to measure levels in amniotic fluid as well as in plasma 
would perhaps be valuable. In view of the apparent lack of both 
synthesis and degradation of prostaglandins in amniotic fluid 
(Keirse 1979) levels in this body fluid may be considered to 
reflect the state of prostaglandin metabolism within the uterus
and feto-placental unit.
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8.5 (b) Patients and Methods
We took samples of amniotic fluid from 27 patients who were 
undergoing amniocentesis for genetic reasons or for «Ifetoprotein 
levels to be measured. Amniotic fluid was immediately placed in 
ice cold tubes containing 1:9 vol 3.8% trisodium citrate with 3 x 
10 ^M Indomethacin. Ihe samples were kept on ice and 
centrifuged within one hour for 15 minutes at 4°C and 250Og. 
Aliquots were stored at -70°C until RIA for PGI^ metabolites 
as described in 3.7.
5 (c) Results
We could find no detectable levels of PGI^ metabolites in any 
of the samples tested except for one patient who had a level of 
62 pg/ml. Her plasma PGI^ metabolite level was 170 pg/ml. 
This patient^ was found to have a foetus with extensive open j  
neural tube defects and subsequently had her pregnancy 
terminated. She was the only patient in the group studied to 
have a positive open neural tube defect.
8.5 (d) Discussion
The reason for the measurable level of PGI2  metabolites in 
amniotic fluid and also for the very high level of plasma PGI2  
metabolites is unclear. It may be related to exposure of damaged 
highly vascular, neural tissue to the amniotic fluid and to 
placental transfer of the PGI2  metabolites. Further work is 
needed in order to substantiate this finding. However it is 
possible that high PGI2  metabolite levels may be a marker for 
such defects.
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8.6 Conclusions
These studies indicate involvement of the prostacyclin 
thromboxane balance in pregnancy induced hypertension. It has 
however yet to be determined whether or not the reduced levels of 
PGI^ metabolites observed in the hypertensive patients appeared 
before the onset of the hypertension and oedema.
Ihe initial observations of failure of platelet rich plasma to 
cause stimulation of PGI^ production from the endothelium of 
umbilical arteries taken from hypertensive patients indicate the 
possibility of an endothelial cell defect.
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CHAPTER 9 - DISCUSSION
9.1 Introduction
When I first started to plan this thesis in 1981 there was much 
excitement and enthusiasm in the prostaglandin field. The 
discovery of prostacyclin (PGI^) was still fairly recent and 
many people saw it as the answer to many clinical thrombotic 
problems. It was thought that since PGI^ stopped platelets 
aggregating, caused vasodilation and relaxed smooth muscle, 
reduced production might be the cause of many vascular and 
thrombotic diseases. Equally, increased production of 
thromboxane A^, which has the directly opposite biological 
actions to PGI^/ might be implicated in many disease states. 
Because of this much time and effort by many researchers all over 
the world was invested in attempts to measure production of 
PGIg and TXA^. As discussed in Chapters 3 and 4 various 
methods were used to measure plasma levels of these two 
substances. Many papers have been published relating imbalance 
of one or other with various disease states. Clinical trials 
were also being performed in many centres using PGI^ infusions 
in various pathological conditions. It almost seemed as if 
PGI2  was the 'flavour of the eighties'. However as more and 
more work was published it soon became apparent that widely 
differing so-called 'normal' plasma levels were being quoted 
especially for 6 -keto-PGFloC, the metabolite of PGI2 . Over the 
five years that it has taken me to complete this work thoughts 
have changed from the euphoric state at the beginning to the 
present, where many people believe that since plasma levels of 
5_l^eto-PGFl oC are now known to be in the low picogram range it is
a waste of time trying to measure it at all.
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Also, since there is such potential for artefactually high levels 
of plasma TXA^ to be generated during blood sanpling and 
processing, the measurement of plasma levels of TXB^, the 
stable metabolite, is also worthless. In this discussion I will 
try to justify my five years of work on these two substances by 
looking at the value of all the methodology described and the 
results obtained using that methodology. I will also discuss 
future work I see resulting from this thesis.
9.2 Value of the methodology developed for the thesis
9.2 (a) Plasma PGI^ metabolite assay
Ihis is probably the measurement that has received most 
criticism over the past few years. It is now generally 
believed that PGI^ does not function as a circulating 
hormone. However since it is known that endothelial cells 
produce PGI2  in response to noxious, chemical and 
mechanical stimuli (Ritter 1983) this does not preclude an 
important local role for PGI2 * For the reasons discussed 
in Chapter 3 we have developed an assay for the measurements 
of PGI2  metabolites in unextracted plasma. Undoubtedly 
absolute values of 6 -keto-PGFl ©C can best be measured by 
negative ion gas chromatography mass spectometry assays, it 
is now generally accepted with P Œ  that measurements of 
only one metabolite gave an abnormal picture and the same 
may be true for PGI2 . It has been shown that only 40% of 
PGI2  is metabolised to 6 -keto-PGFl oC (Myatt 1981) and 
there has been little published work on the remaining 50% of 
metabolites such as 13,14-dihydro-6,15 diketo-PGFl©C .
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We have validated our assay as described in 3.7 and believe that 
we are measuring metabolites of PGI2 . Since normal levels have 
been shown to be very near to the lower limit of detection of the 
assay it is not possible to detect any decrease in PGI^ 
production using this method. However in situations where 
elevated levels of PGI2  are to be expected it would seem to be 
a potentially useful measurement, ihe elevated levels we have 
found in certain vascular diseases as discussed in Chapter 6  may 
help our understanding of the pathology of these diseases. 
Except possibly in the case of pregnancy induced hypertension it 
is not of use as a diagnostic assay but, in retrospect, the time 
spent in the development of the assay has I feel not been wasted.
9.2 (b) Prostacyclin stimulating factor assay and umbilical artery
perfusion model
As discussed in detail in Chapter 3, the PGlg stimulating 
factor assay using umbilical artery rings has limitations and 
hence justified the development of our umbilical artery perfusion 
model. However if one wishes to examine several samples for the 
presence of this PGI2  stimulating factor, the umbilical artery 
ring method is much quicker and allows selection of samples which 
do not contain stimulating factor. Such selected samples can 
then be assayed more effectively and accurately using the 
umbilical cord perfusion model. The umbilical artery perfusion 
method is a more physiological model than the rings and is more 
useful in the assessment of the effects of drugs on endothelial 
cell PGI2  production. Perhaps its principal limitation is in 
the number of samples generated for RIA of PGI2  metabolites 
which is an expensive assay to perform and hence the reason for
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many of our experiments using this model not being repeated as 
often as one would wish. Our initial findings of the failure of 
normal platelet poor plasma to stimulate endothelial cell
production of PGI2  in arteries from patients with pregnancy 
induced hypertension deserves further study using this model.
9.2 (c) Plasma TXB2  assay
Measurement of plasma levels of TXB2  is liable to give
artefactually high levels due to platelet activation at 
venepuncture. It is open to question whether what we are
measuring is in fact purely thromboxane produced in response 
to venepuncture. Like PGI2  it is now generally thought that
TXA2  does not act as a circulating hormone but is produced in 
response to local stimuli. It would seem that, if we wish to 
measure the ability of platelets to produce TXA2  ^ serum TXB2  
levels would give a more reliable index Since it is less liable 
to give artefactually high levels. However all sanples used for 
this thesis were taken using a standard venepuncture technique 
and all samples associated with traumatic venepuncture were 
discarded. In future studies however serum TXB2  levels would 
seem to be a more reliable measurement to use.
9.2 (d) Serum TXB2 , Serum TXB2  in bleeding time blood
and thromboxane generation 
As discussed in 4.5, provided blood is immediately incubated at 
37 C aîter venepuncture, serum TXB2  levels give a reliable 
measurement of the ability of platelets to generate thromboxane 
A2  in response to the endogenous stimulus of thrombin generated 
during blood clotting. The thromboxane generation assay gives a 
measurement of the ability of platelet to generate thromboxane
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in response to the exogenous stimulus of collagen 4  /ig/ml.
It would perhaps appear from the dose response curve we obtained 
for collagen (figure 4.2) that 8 /jg/ml of collagen would be a 
more suitable dose to use in order to obtain maximum
aggregation. However results at this dose are much more variable 
and A j i g / m l  would seem to be a more satisfactory stimulant.
Ihe measurement of serum TXB^ from bleeding time blood would 
appear to give no more information than normal serum levels. 
However it gives us an indication of serum TXB^ levels in
response to injury rather than when blood is simply left to clot 
in vitro. It could therefore be argued that it is a more
physiological method to use. However the disadvantage of
subjecting the patients to a bleeding time test must be weighed 
against this. When a patient's bleeding time has to be measured 
for other reasons it would seem to be worthwhile to measure the 
serum levels of TXB2  from the site of the incision especially 
in the case of unexplained bleeding disorders.
9.3 Hie importance of the prostacyclin/thromboxane balance in the 
clinical situation
Since a large part of this thesis is concerned with development 
and evaluation of methodology for the measurement of PGI2  and
production we must therefore decide in retrospect whether ;
or not it was worthwhile. The initial normal volunteer study on 
diet indicates no involvement of PGI2  or TXA2  in the 
mechanism by which a saturated fat diet produces platelet 
activation. Although negative findings are usually disappointing 
to the researcher they still contribute to our knowledge albeit 
negatively. In the study on smoking we measured only plasma
PGI2  metabolite levels and showed an increase of PGI2
- 139 -
metabolites after smoking, though the small numbers prevent this 
being statistically significant. It would have been interesting 
to measure TXB^ levels in this study but we were unable to 
obtain a sufficient volume of blood. This initial study however 
warrants further investigation of the effect of smoking on the 
thromboxane/prostacyclin balance.
Our studies on vascular disease showed the perhaps unexpected 
results of increased levels of PGI^ metabolites associated with 
severe vascular disorders. This finding points to the need for 
further studies to try to determine whether this is a 
compensatory mechanism; whether there is cellular resistance or 
whether there is decreased platelet sensitivity to PGI^ due to 
exposure to persistently high levels of PGI2 . In these 
vascular studies we decided initially to measure plasma TXB2  
levels. Since most of these patients were having blood samples 
taken for other biochemical tests we were unable to obtain 
sufficient blood for both tests.
In retrospect measurement of serum levels would perhaps have been 
of more value and we have a study in progress where serum levels 
of TXB2  are being measured.
The results from the studies on bleeding disorders show lower 
levels of plasma PGI^ metabolites in patients with von 
Willebrand's disease and also a lower percentage increase after 
infusion of DDAVP \^en compared to normals or haemophiliacs 
perhaps indicating some defect in endothelial cell production. 
The report on the patients with a possible thromboxane synthetase 
deficiency is of interest and warrants further study of the 
patient and her family.
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Our studies on pregnancy and associated diseases indicate 
involvement of the prostacyclin, thromboxane balance in pregnancy 
induced hypertension and our preliminary findings of the 
inability of normal platelet poor plasma to stimulate PGIg 
production from the endothelium is of great interest.
9.4 The way ahead
Perhaps the one thing I have noticed most of all when writing the 
results of this work is the need for more work. As our knowledge 
of a subject develops so does our quest for yet more knowledge 
and we may never reach the end. From this viewpoint alone 
therefore the work presented in this thesis would seem to be 
worthwhile. The initial development and evaluation of the 
methodology has enabled us to see which methodology is the most 
useful for future studies. I feel a larger study on smoking 
would be worthwhile using large numbers to try to discover 
whether or not there are any differences in PGI2  metabolite 
levels in smokers who develop smoking related diseases and those 
who do not. It could conceivably be that the suggestion of 
increased PGI2  metabolite levels we have noticed after smoking 
in some smokers is a defence mechanism which fails in some people 
thus leading to vascular and other disorders. There is much 
research being performed at present by drug companies in the 
development of PGI2  analogues suitable for oral and transdermal 
administration. Measurement of plasma PGI2  metabolites in 
patients using these preparations would give some indication of 
absorption. A study of thromboxane generation both by endogenous 
stimulus in serum and generation by the exogenous stimulus of
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collagen would be worthwhile in patients with various vascular 
diseases and this has in fact been started. The use of the 
various indices of thromboxane generation described in Chapter 4 
will also be useful in the future investigation of patients 
suffering from unexplained bleeding disorders.
More work with larger numbers must be done to discover if our 
initial findings suggesting a defect in endothelial PGI2  
production associated with pregnancy induced hypertension is in 
fact true and whether this could also be associated with other 
types of hypertension.
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